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ABSTRACT 
This dissertation explores the nature of a divergent member of the Transforming 
Growth Factor-β [beta] superfamily, the non-steroidal anti-inflammatory drugs activated 
gene (NAG-1), as it relates to its regulation and biological activity in cancer context. Our 
lab has extensively studied on the molecular mechanism by which phytochemicals and 
NSAIDs induce apoptosis correlation with NAG-1 expression in human colorectal 
cancer (CRC) cells. Significant data from in vitro studies suggest that NAG-1 has an 
anti-tumorigenic activity which elicits apoptosis in a cyclooxygenase (COX)-independent 
manner in CRC cells. Indeed, NAG-1 transgenic mice developed less aberrant polyp 
foci (APC) compared to those of control counterpart in chemically- , genetically induced 
colorectal cancer models. However, it has been reported that NAG-1 has a tumor-
promoting activity in a different cancer type such as prostate cancer and in chapter 1, a 
literature review for the regulation and the role of NAG-1 in the context of cancer will be 
discussed. Human pancreatic cancer cells treated with the PPARγ [gamma] ligand 
MCC-555 showed the feature of apoptosis with associated with NAG-1 induction. MCC-
555 induces KLF4 expression via PPARγ-independent pathway, which in turn induces 
NAG-1 transactivation by which KLF4 binds to NAG-1 promoter region, suggesting 
NAG-1 is also implicated in apoptosis in human pancreatic cancer cells (Chapter 2). 
During the study on the signaling pathway and target genes affected by NAG-1, we 
observed nuclear expression of NAG-1. Nuclear NAG-1 moderates TGFβ signaling by 
interfering binding of Smad complex to DNA, leading to the inhibition of cell migration 
and invasion induced by TGFβ signaling (Chapter 3). Taken together, the studies 
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presented in this dissertation suggest that NAG-1 maybe a driver factor for apoptosis 
not only in CRC cells, but in pancreatic cancer cells, and this effect might arise from the 
activity of nuclear NAG-1 which attenuates Smad signaling required for cancer survival 
and progression.  
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This dissertation explores the nature of a divergent member of the Transforming 
Growth Factor-β superfamily, the non-steroidal anti-inflammatory drugs activated gene 
(NAG-1), as related to its regulation and biological activity within cancer context. Our lab 
has extensively studied this divergent member of the Transforming Growth Factor-β 
superfamily on the molecular mechanism by which phytochemicals and NSAIDs induce 
apoptosis correlation with expression of this gene in human colorectal cancer (CRC) 
cells. Significant data from in vitro studies suggest that NAG-1 has an anti-tumorigenic 
activity which elicits apoptosis in a cyclooxygenase (COX)-independent manner in CRC 
cells. Indeed, NAG-1 transgenic mice developed fewer aberrant polyp foci (APC) 
compared to those of control counterpart in chemically- , genetically induced colorectal 
cancer models. However, it has been reported that NAG-1 has a tumor-promoting 
activity in a different cancer type such as prostate cancer. It has been demonstrated 
that the cellular context including epigenetic status and protein expression profiling in 
cancer is the crucial key which tunes cellular behavior to proper response to stimulus. 
There is the need to study NAG-1 in other cancer type which in NAG-1 might elicit a 
different biological consequence.  
The regulation and the role of NAG-1 in the context of cancer will be discussed 
within chapter 1 literature review. Since NAG-1’role in pancreatic cancer has not been 
well documented, we employed pancreatic cancer cells to study if NAG-1 can be 
induced in this cancer type. Human pancreatic cancer cells treated with the PPARγ-
ligand MCC-555 showed the feature of apoptosis with associated with NAG-1 induction. 
MCC-555 induces KLF4 expression via a PPARγ-independent pathway, which in turn 
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induces NAG-1 transactivation through the binding of KLF4 to the NAG-1 promoter 
region, suggesting NAG-1 is also implicated in apoptosis in human pancreatic cancer 
cells (Chapter 2). During the study on the signaling pathway and target genes affected 
by NAG-1, we observed nuclear expression of NAG-1. Nuclear NAG-1 moderates TGFβ 
signaling by interfering with the binding of the Smad complex to DNA, leading to 
inhibition of cell migration and invasion induced by TGFβ signaling (Chapter 3).  
Taken together, the studies presented in this dissertation suggest that NAG-1 
maybe a driver factor for apoptosis not only in CRC cells, but in pancreatic cancer cells, 
and this effect might arise from the activity of nuclear NAG-1 through attenuation of 
Smad signaling required for cancer survival and progression.  
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CHAPTER 1 
 
NAG-1 in cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5 
 
1.1 Introduction 
Nonsteroidal anti-inflammatory drug (NSAID) activated gene-1 ( NAG-1), a TGF-
β superfamily gene, was discovered and identified by several different groups, referring 
as macrophage inhibitory cytokine - 1 [1], placental transformation growth factors 
(PTGFB) [2], prostate-derived factor (PDF) [3], growth differentiation factor 15 (GDF15) 
[4], or placental bone morphogenetic protein (PLAB) [5]. Because the method strategies 
used for finding this protein arise from different cellular context, NAG-1 may have a 
multiple facet to response to different environmental questions. In the context of cancer 
as with other members of the TGFβ superfamily, both an anti-tumorigenic and pro-
tumorigenic potential of NAG-1 have been demonstrated [6], yet it’s the molecular 
mechanism(s) remain to be resolved, including elucidation of NAG-1’s downstream 
signal pathway and its receptor(s).  
Transcriptional regulation of NAG-1 has been well studied, compared to the 
biological consequence induced by NAG-1 expression. It has been reported that dietary 
compounds, NSAID(s) and PPAR ligands induce the activation of up-stream signal 
molecule such as p53, EGR-1 and KLF4, responsible for NAG-1 trans-activation in 
various cancer cell lines. In this case, NAG-1 expression seems to be implicated in the 
inhibition of tumor cell growth.  
Upon discovery of dynamic protein localization, NAG-1 could be subjected to 
study its cellular localization, although it has been characterized as a secretion protein 
like other TGF-β superfamily proteins. Since secretion protein observed in intra-cellular 
region [7], it is plausible that NAG-1 also has second location where it resides in and 
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performs a different function, which in part could explain divergent roles of NAG-1 in 
cancer. By dissecting NAG-1’s role on molecular level(s) during tumorigenesis, NAG-1 
may serve as a potential biomarker/or a therapeutic target for the diagnosis and 
treatment during cancer progression.  
 
1.2 Transcriptional regulation of NAG-1 
Many trans-acting transcription factors that control NAG-1 induction have been 
identified, including p53, early growth response gene-1 (EGR-1), Sp1, activating 
transcription factor-3 (ATF-3) and Kruppel-like factor 4 (KLF4).  A variety of dietary 
compounds, NSAIDs and PPARγ ligands have been reported to induce NAG-1 
expression through the activation of these transcription factors in various cancer cell 
lines.  
p53 is classified as a tumor suppressor gene and plays a pivotal role in 
apoptosis, genomic stability and controlling cell cycle. NAG-1 promoter contains p53 
binding sites and NAG-1 expression can be mediated by p53 expression induced by 
natural products, leading cell growth arrest and apoptosis in cancer cells [8]. EGR-1 
plays a role in the regulation of cancer cell growth and differentiation and EGR-1 is a 
direct regulator of multiple tumor suppressors [9], though EGR-1 also possesses tumor-
promoting effect in prostate cancer [10], suggesting that EGR-1’ role in cancer is 
dependent on cellular context. EGR-1-binding sites are located within region -73 to -51 
of the NAG-1 promoter and have an important role in the transactivation of PPARγ 
ligand-induced NAG-1 expression [11].  
 7 
 
ATF3 is a member of the ATF/CREB superfamily and its expression is 
dramatically induced in response to extracellular signals [12]. Recently, it has been 
reported that NAG-1 can be induced by cooperation of transcriptional machinery. In 
colorectal cancer cells, capsaicin, a natural product of red peppers induces nuclear 
accumulation of GSK3β which phosphorylates C/EBPβ. ATF3 plays a role as a bridge 
protein to make complex with activated C/EBPβ by capsaicin for enhancing binding 
affinity of C/EBPβ onto NAG-1 promoter and activates transcription of NAG-1 gene [13].  
KLF4 is a zinc finger transcription factor, and its high expression level has been 
observed in postmitotic, differentiated epithelial cells of the skin and the gastrointestinal 
tract [14, 15]. Ectopic expression of KLF4 leads to cell-cycle arrest by the ability of KLF4 
to express p21 [16], and KLF4 suppresses cyclin D1 at the transcriptional level [17], 
suggesting that KLF4 may serve as a tumor suppressor. Loss of expression of KLF4 
has been observed in human tumor associated with a more aggressive phenotype [18], 
and conditional KLF4-knockout mouse model develop hyperplasia and polys in their 
stomachs [19], suggesting KLF4 can indeed function as a tumor suppressor gene. It has 
been reported that NAG-1 is up-regulated byKLF4 activation. KLF4 expression by a 
PPARγ ligand controls the NAG-1 promoter activity in human and mouse colorectal 
cancer [20]. In chapter 2, KLF4 as a trans-acting element for NAG-1 expression in 
pancreatic cancer cells will be discussed.  
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1.3 The controversial role of NAG-1 in cancer development  
Even though NAG-1 expression is under control of tumor suppressor proteins 
such as p53, Egr-1 and KLF4, its implication in cancer development is still unclear. The 
anti-tumorigenic and pro-tumorigenic effects of NAG-1 seem to be context dependent. 
The high serum level of NAG1 in colorectal cancer patient has been reported, and NAG-
1 serum level was proposed as a prognostic marker for disease progression [21].        
NAG-1 shows a tumor suppressor effect in cell culture system [22]. The study with 
NAG-1 transgenic mice demonstrates NAG-1 has the anti-tumorigenic activity in 
chemical induced or genetic colorectal cancer models [23]. In prostate cancer, NAG-1 
has been shown to induce growth arrest in DU145 human prostate carcinoma cells and 
implicated in apoptosis by caspase-3 activation [24]. Ectopic expression of NAG-1 in 
PC-3 cells inhibited proliferation and the growth of these cells in a xenograft tumor 
model [25]. However, significant data also have shown that NAG-1 induces prostate 
cancer cell migration and invasion [26]. NAG-1 also increases cell proliferation of 
LNCaP cells through ERK activation [27]. Plasma levels of NAG-1 was associated with 
prostate tumor progression and NAG-1 expression has been observed in human 
prostate cancers [28, 29], suggesting that NAG-1 might be a target for a diagnostic 
maker in prostate cancer. Elucidating biological regulation, downstream pathways and 
target genes of NAG-1 could decipher the dichotomy of NAG-1 in cancer progression.  
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1.4 The diverse subcellular localization of proteins and its implication 
in new biological function of NAG-1 in cancer context  
The idea of one gene - one protein - one function has become too simple to 
explain the cellular complexity since 20,000 -25,000 human protein-coding genes are 
currently estimated. Although alternative splicing mechanism could partially explain this 
discrepancy, it still requires another way for our understanding of cellular complexity. A 
growing number of multifunctional proteins in which the two functions are found in a 
single polypeptide chain, are being identified and give us a new insight for deciphering a 
complex modern cell.  
Emerging data on cellular localization of proteins unravels additional activities of 
proteins by changing their subcellular localization apart from the region where proteins 
are first destined. One single cellular compartment (cytoplasmic, nuclear, plasma 
membrane or extracellular region) in which each protein primarily resides and functions 
was considered to characterize a protein in the classical view [30]. However, 
unexpected subcellular localization of such proteins changes this classical view, and 
gives us one of mechanism for multifunctional protein which may represent a new 
mechanism through which cells overcome the limited amount of genomic information to 
fulfill a complex biological behavior.   
 Although such proteins were identified and categorized based on a single 
activity, each is now known to display multiple, independent functions beyond those 
from which they were identified originally, and these multifunctional proteins are also 
referred to as “Moonlighting proteins” [31]. Moonlighting refers to a single protein that 
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has multiple functions that are not result of gene fusions, families of homologous 
proteins, splice variants, or promiscuous enzyme activities. It is speculated that 
ancestral moonlighting proteins originally possessed a single function but through 
evolution, acquired additional functions [32]. In addition to a change in cellular location, 
moonlighting proteins can switch between functions due to a change in temperature, a 
change in the redox state of the cell, a change in oligomeric state of the protein, 
interactions with different polypeptide chains in different protein complexes, or changes 
in the cellular concentration of a ligand, substrate, cofactor, or product [33, 34].                            
Although these switching conditions are all considered as mechanism(s) for 
moonlighting, this review is to only catalog well known proteins in which a change of 
subcellular localization contributes to additional function of proteins (Fig. 1.1).                                                                              
 
1.4.1. Transcription factor  
 
1.4.1.1. p53 tumor suppressor protein 
p53, a well- known tumor-suppressor protein, accumulates in the nucleus in 
response to DNA damage, oncogene activation or other cellular stresses, where it acts 
as a nuclear transcription factor by binding to specific DNA sequence to regulate a 
variety of genes [35, 36]. In addition to this nuclear activity, p53 has also been reported 
to exhibit a different biological activity in the cytoplasmic region than that of a 
transcription factor [37]. Wherein mutant p53 losing transcriptional activity still has the 
ability to induce apoptosis [38].  
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Figure 1.1 Multifunctional proteins 
A protein can be localized in multiple subcellular regions. Altered subcellular 
localization results in a different function. Red colored proteins indicate that they 
originally reside in the subcellular region where they are categorized in. TG2, 
transglutaminase 2; Hsp90, heat shock protein 90; HMGB1, high-mobility group 
protein B1; MMP, matrix metalloproteinase; bFGF, basic fibroblast growth factor; 
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; CCN2, connective tissue 
growth factor.  
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There are reports that p53 rapidly accumulates to the mitochondria under a variety of 
stress conditions [39]. The mitochondrial membrane is one of intracellular compartment 
where cytoplasmic p53 is located under a stress condition and induces mitochondrial 
outer membrane permeabilization by triggering the release of pro-apoptotic factors such 
as Bax and Bak, [40, 41]. This indicates that the pro-apototic effects of cytoplasmic p53 
are independent of transcription. Post-translational modification of p53 and protein 
interactions can dictate destination of p53 [39, 42]. Together, it is likely that apoptosis 
induced by p53 arise from combined activities of the cytoplasmic and nuclear proteins.  
 
1.4.1.2. Smads 
Smad transcription factors are downstream mediator of TGFβ superfamily 
cytokines, and eight Smad proteins have been identified in human and mouse [43]. 
Smad1, Smad2, Smad3, Smad5 and Smad8 are substrates for TGFβ receptors, 
referred to as receptor-regulated Smads, or R-Smads. Smad4 interact with R-Smads as 
a common partner for all Rsmads, also referred to as Co-Smad. Smad6 and Smad7 are 
inhibitory Smads, also referred to as I-Smad that attenuates the interaction between 
Smad-receptor or Smad-Smad interaction [44]. R-Smads constantly shuttle between the 
cytoplasm and the nucleus in the basal state to monitor if TGFβ receptors are activated. 
Upon ligands binding, phosphorylated R-Smad by its receptor can be recognized by Co-
Smad (Smad4). This this complex can then enter the nucleus more rapidly to regulate 
appropriate gene expression together with other DNA-binding cofactors based on 
specific cellular context [45, 46]. This is originally characterized by the role of R-Smads 
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and Smad4 in the nucleus as a transcription factor mediating TGFβ signaling. However, 
Smad proteins could also act as an adaptor protein in the cytoplasm to regulate other 
signal pathways. Notably, Dvl-1, Erbin, and Par-3 have been identified as Smad3 
binding proteins using a yeast two-hybrid screen, suggesting that Smads can directly 
interact with these proteins, not as a transcription factor, but to regulate cell polarity [47]. 
Smad3 also binds to collagen types I, III, and V implying another aspect of smad 
proteins, not served as a transcriptional factor  in the developing orofacial region [48]. 
Smad4 binds to Hoxa9 proteins in the cytoplasm to prevent nuclear translocation of 
Hoxa9, suggesting a protective role of Smad4 against nuclear activation by Hoxa9 and 
leukemia transformation [49]. This indicates that monitoring activation of TGFβ receptor 
is not the only task which Smad proteins perform for ultimately regulation of gene 
expression. Remarkably, Smad proteins interact with different components of other 
pathway in the cytoplasm [50], as an adaptor or an anchor protein for fine tuning and 
cross-talking of TGFβ signal with other signaling pathways.  
 
1.4.2. Cytoplasmic proteins 
 
1.4.2.1. Hsp90 
Heat shock protein 90 (Hsp90) is a molecular chaperone of cytoplasmic proteins, 
mediating the ATP-dependent folding, stabilization, intracellular disposition and 
proteolytic turnover of proteins [51, 52]. However, Hsp90 is also a secreted and cell 
surface protein. The Hsp90 secreted form is considered a pro-tumorigenic protein as 
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blocking this form showed significant inhibition of tumor metastasis while serum level of 
Hsp90 positively correlates with tumor malignancy in clinical cancer patients [53]. 
Extracellular Hsp90 interacts with and stabilize matrix metalloproteinase-2 (MMP-2) that 
contributes to angiogenesis and cancer cell invasiveness [54, 55]. Secreted Hsp90 has 
also been reported to regulate and alter E-cadherin function in prostate cancer, giving 
rise to EMT [56], indicating it can be a diagnostic marker for tumor malignancy. In 
addition to this unexpected role of Hsp90 in the extracellular region, while Hsp90 has 
also been found in the nucleus [57] and could regulate several nuclear events [58].  
 
1.4.2.2. Transglutaminase 2 
Transglutaminase 2 (TG2), a ubiquitous member of the mammalian 
transglutaminase family, can catalyzes protein cross-linking via transamidation of 
glutamine residues to lysine residues in a Ca2+-dependent manner [59]. Besides its 
classical protein crosslinking activity, TG2 possesses several other functions in a 
different cellular compartment including G protein, cell adhesion, kinase activities. TG2 
is predominantly a cytoplasmic protein, but increasing evidences indicate that TG2 
dynamically translocate depending on cellular context [60], even though molecular 
mechanism(s) underlying dynamic translocation of TG2 to various subcellular 
compartments remains elusive. In addition to transglutaminase (TGase) activity, 
cytosolic TG2 has been shown to be involved in signal transduction. TG2 activates NF-
κB pathway to elicit anti-apoptotic effects in ovarian cancer cells [61]. TG2 can function 
as a G protein (Gh) on the plasma membrane which has a unique GTP binding pocket 
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and GTP hydrolysis activity, suggesting TG2 may be implicated in receptor signaling 
[62]. Membrane TG2 was also shown to have a kinase activity. TG2 isolated from 
membrane fractions was found to phosphorylate insulin-like growth factor-binding 
protein-3 (IGFBP-3) [63]. Translocation of TG2 from the cytoplasm to the nucleus has 
been reported in various cell types [64-66] which shows how a versatile protein TG2 is. 
Although elevation of intracellular calcium levels promoted TG2 translocation to the 
nuclear compartment [66], biological function of nuclear TG2 is still unclear. Emerging 
evidence indicates the importance of nuclear TG2 in regulating gene expression via 
post-translational modification of transcriptional factors (via crosslinking and 
phosphorylation) and histone proteins. These include E2F1 [67], hypoxia inducible 
factor 1[68], Sp1[69] and all four mammalian core histones (H2A, H2B, H3 and H4) [70]. 
Although TG2 has been originally identified as an intracellular enzyme, TG2 even was 
found in extracellular space. Extracellular TG2 acts as a matrix stabilizer through its 
protein cross-linking and as an important cell adhesion protein involved in cell survival 
[71]. Extracellular TG2 has been reported to associated with multiple integrins of the β1 
and β3 subfamilies implicated in cell adhesion and spreading [72]. TG2 also interacts 
with extracellular matrix-associated fibronectin (FN). FN-bound TG2 with increased 
resilience to MMP degradation maintains cell adhesion by interacting with cell surface 
heparin sulfate chains of syndecan-4 [73]. These substantial observations indicate that 
various activities of TG2 are differentially regulated depending on its subcellular 
localization. 
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1.4.2.3. GAPDH 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) catalyzes an important 
energy-yielding step in glycolysis in which GAPDH coverts glyceraldehyde-3-phosphate 
to D-glycerate 1,3-bisphospate  in the presence of inorganic phosphate and 
nicotinamide adenine dinucleotide (NAD), mediating formation of NADH and adenosine 
triphosphate (ATP). In addition to this originally identified function as a “housekeeping” 
protein in the cytoplasm, emerging data exhibits numerous activities apart from energy 
production [74, 75]. GAPDH is translocated to the nucleus upon exposure to a stressor 
such as oxidative stress leading to cell death/dysfunction [76]. This nuclear 
translocation is mediated by S-nitrosylation at Cys-150, allowing GAPDH to bind to Shia 
spanning nuclear localization signal, resulting in nuclear translocation of this GAPDH-
Siah complex. Nuclear GAPDH is further acetylated at Lys 160 by the acetyltransferase 
p300/CREB binding protein (CBP) through direct protein interaction, which in turn 
stimulates the acetylation and catalytic activity of p300/CBP, leading to induce its target 
genes including the tumor suppressor p53 [77]. Various functions of GAPDH in the 
nucleus that deviate from cell death have also been reported. GAPDH directly interacts 
with APE1 involved in the base excision DNA repair pathway. GAPDH reactivate 
endonuclease activity of APE1 to cleave a basic site and to regulate the redox state of a 
number of transcriptional factors such as p53, AP-1, c-Jun, cFos and NF-κB  [78]. 
GAPDH binds to and makes complex with Oct-1-p38/GAPDH to regulate transcription 
required for S-phase progression in cell cycle [79]. Nuclear GAPDH also plays a role in 
maintaining and protecting telomeric DNA from chemotherapy-induced rapid 
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degradation [80]. Through these finding, GAPDH is not only believed to be involved in 
glycolysis as a cytoplasmic protein, but also participated in gene regulation as a nuclear 
factor.  
 
1.4.3. Nuclear protein 
 
1.4.3.1. HMGB1 
High mobility group box-1 (HMGB1) belongs to three families (HMGA, HMGB 
and HMGN), and members of each family have been identified as the second most 
abundant chromatin proteins, participating in gene regulation and cellular differentiation 
[81]. Moreover, they contribute to the fine tuning of transcription in response to rapid 
environmental changes by interacting with nucleosomes, transcription factors, 
nucleosome-remodeling machines, and with histone H1 [82]. HMGB1 regulates 
transcription by binding with nucleosomes to loose packed DNA and remodel the 
chromatin, which facilitates the binding of other proteins to DNA. HMGB1 was 
previously thought to function only as a nuclear factor. However, this protein was 
recently discovered to be a crucial cytokine that mediates the response to infection, 
injury and inflammation [83]. HMGB1 was found to be released by cultured 
macrophages more than 8 hours after stimulation with endotoxin, TNF, or IL-1. 
Releasing HMGB1 was considered as a cytokine involved as a late-acting mediator for 
lethal shock (endotoxemia) because HMGB1 release occurs considerably later than 
secretion of the classical early pro-inflammatory mediator TNF and IL-1 [84]. HMGB1 
bind to the receptor for advanced glycation end-products (RAGE) and to the Toll-like 
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receptors (TLRs) for activating the inflammatory process in immune and endothelial 
cells [85, 86], and has been intensively reviewed. Secretion of HMGB1 seems not to be 
restricted to immune cells since epithelial gastric and colon cancer cell lines also 
release HMGB1 [87]. 
 
1.4.4. Plasma membrane proteins 
 
1.4.4.1. E-Cadherin 
E-cadherin is a class I transmembrane glycoprotein which plays an important 
roles in cell adhesion, forming adherens junctions and facilitating the formation of the 
entire epithelial junctional complex.  This identifies function of this protein as a cell 
membrane protein [88, 89]. E-cadherin contain 5 cadherin repeats (EC1 ~ EC5) within 
the extracellular domain that bind calcium ions to form a stiffened linear molecule, one 
transmembrane domain, and an intracellular domain that interacts with the catenins and 
a variety of actin-binding proteins to anchor the cadherin–catenin complex to the actin 
cytoskeleton [88]. β-catenin is a protein that binds to intracellular domain of E-cadherin 
and intense studies have shown that β-catenin can localize in the nucleus and play a 
key role in signal transduction in the canonical Wnt signaling pathway [90]. E-cadherin 
can also block growth factor–mediated proliferation signaling (contact inhibition of 
growth), thereby maintaining tissue integrity and preserving tissue function [91]. 
Decrease in E-cadherin attenuates strong cell-cell interactions supporting cancer 
progression and metastasis [92]. Since lowering the strength of cellular adhesion within 
a tissue gives rise to cancer cell motility, enabling cancer cells to cross the basement 
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membrane and invade surrounding tissues. Reduced expression of E-cadherin is 
indicative of unfavorable clinical outcome in several malignant diseases [93]. These 
findings support the notion that E-cadherin may be a tumor-suppressor protein. 
However, emerging roles of nuclear E-cadherin as a modulator of tumor growth survival, 
and motility, triggering cancer progression, have been reported as E-cadherin may also 
possess oncogenic functions. E-cadherin has been shown to be cleaved by γ-secretase 
wherein the E-cadherin cytoplasmic fragment translocates to the nucleus and regulate 
gene expression [94]. This implies that oncogenic functions of E-cadherin may arise 
from cleaved translocated form in the nucleus. Nuclear E-cadherin fragment interacts 
with CTF2 to suppress the induction of apoptosis [94]. In vivo studies have shown that 
detection of aberrant nuclear E-cadherin correlates with lymph node spread and liver 
metastases in pancreatic endocrine tumors [95]. In addition to γ-secretase, several 
proteases, matrix metalloproteinases (MMP-3, MMP-7, MMP-9, and MT1-MMP) have 
also been reported to converts the mature 120 kDa E-cadherin into an extracellular N-
terminal 80-kDa fragment and an intracellular C-terminal 38-kDa fragment [96]. 
Interestingly, the extracellular fragment is released from the plasma membrane and 
diffuses into the extracellular environment and even the bloodstream to serve as a 
paracrine/autocrine signaling molecule [97].  
 
1.4.4.2. TGF-β receptor I 
TGFβ receptors are type I transmembrane proteins which possess 
serine/threonine kinase activity. In the canonical pathway, active TGF-β1 binds to cell 
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surface receptor kinases TGF-β type I (TβRI) and type II receptors (TβRII). Upon ligand 
binding to TβRII, TβRII further phosphorylates and activates TβRI, which in turn 
propagates the signals by phosphorylating Smad proteins  [98], which are 
aforementioned, to regulate cell  differentiation, morphogenesis, tissue homeostasis and 
regeneration. This function as a cell membrane receptor for sensing and propagate 
signal is originally identified the role of TGFβ receptors. Since TNF-alpha converting 
enzyme (TACE) has recently been shown to cleave TβRI and releases ectodomains, 
which was demonstrated to cause a decrease in TGFβ signaling [99], Yabing Mu’s 
group has further investigated and have shown that TGFβ induces Lys63-linked 
polyubiquitination of TβRI  via TRAF6 to promote cleavage of TβRI by metalloprotease 
TNF-alpha converting enzyme (TACE), resulting in translocation of the intracellular 
domain of TβRI to the nucleus [100]. After the liberated intracellular domain (ICD) of 
TβRI is translocated to the nucleus, it associates with the transcriptional regulator p300 
to activate genes involved in tumor invasion, such as Snail and MMP2, suggesting how 
TGFβ promotes tumor progression. n. Another recent report has shown that ligand-
stimulated TβRI is translocated to the nucleus in association with importin β1, nucleolin, 
and Smad2/3 inHER2-transformed cells. In the nucleus, TβRI specifically recognizes 
RNA targets and regulates RNA processing in the nucleus [101].  
 
1.4.4.3. EGFR 
The epidermal growth factor receptor (EGFR) is a member of the EGFR tyrosine 
kinase family, which consists of EGFR (ErbB1/HER1), HER2/neu (ErbB2), HER3 
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(ErbB3) and HER4 (ErbB4) triggering intracellular signaling pathway by phosphorylating 
downstream signal molecules such as the RAS/MAPK, PI(3)K/Akt, PLCγ/PKC, and 
Jak/STAT. EGFR stimulates downstream cell signaling cascades that influence cell 
proliferation, apoptosis, migration, survival and complex biological processes. There are 
many reports that EGFR has been consistently detected in the nuclei of cancer cells 
from primary tumor specimens and highly proliferative tissues [102, 103], suggesting a 
second function of EGFR as a nuclear factor in addition to traditional cytoplasmic 
signaling. Research over the last decade has demonstrated the mechanism(s) of 
transport of EGFR to the nucleus. The EGFR family members (EGFR, ErbB2, ErbB3, 
and ErbB4) have conserved tripartite nuclear localization signal (NLS) which can be 
recognized by importin β1 for shuttling EGFR to the nucleus [104]. EGFR is described 
to undergo COPI-mediated retrograde trafficking from the Golgi to the ER [105] then 
EGFR is translocated to the inner nuclear membrane (INM). Molecular mediators for 
nuclear translocation of EGFR include dynamin, importins and Sec61 [106], and CRM1 
exportin may be involved in the nuclear export of EGFR [107]. Upon entry into the 
nucleus, the EGFR can function in ways distinct from the receptor tyrosine kinase on 
plasma membrane. Many reports have indicated a role of nuclear EGFR, which act as a 
co-transcription factor by interacting with transcription factors including E2F1 and 
STAT3 [108-110]. These findings suggest that the subcellular distribution of EGFR 
contribute to elicit different biological outcomes and need to be taken into consideration 
in the field of EGFR studying.  
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1.4.5. Secreted proteins 
 
1.4.5.1. MMPs 
Matrix metalloproteinases (MMPs) were originally identified as zinc-dependent 
endopeptidases that act in the extracellular matrix. Most studies on the MMPs have 
been traditionally associated with the degradation and turnover of most of the 
extracellular matrix (ECM) components, contributing to tissue destruction, remodeling 
and pathological process such as tumor cell invasion [111, 112]. Emerging data have 
uncovered nontraditional roles for MMPs in the extracellular space as well as in the 
nucleus [113]. The biological role of intracellular located MMPs and mechanism(s) for 
protein trafficking are still unclear, although recent studies have demonstrated some of 
their functions in intracellular regions and mechanism(s) for protein trafficking. The 
presence of MMP-2 in the nucleus of cardiac myocytes has been reported. Poly (ADP-
ribose) polymerase (PARP) may be a nuclear substrate of MMP-2 suggesting a 
possible role of nuclear MMP-2 in PARP degradation [114]. MMP-3 is also found in the 
nucleus of several cultured cell types and in human liver tissue sections. MMP-3 may 
have the putative NLS at position 107 to 113 in amino acid sequence which is 
responsible for nucleus entry. Nuclear expression of MMP-3 is associated with an 
increased rate of apoptosis although the mechanism is unclear and may serve as an 
anti-tumorigenic protein [115]. Additional putative NLS in MMP-3 have been found and 
show another role in the nucleus as a transcriptional factor. MMP-3 binds to a 
transcription enhancer in the connective tissue growth factor (CCN2/CTGF) promoter 
and activates transcription of CCN2/CTGF [116] which promotes physiological 
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chondrocytic proliferation and ECM formation, suggesting a novel role of MMP3 in the 
development, tissue remodeling, and pathology of arthritic diseases through 
CCN2/CTGF modulation. MMP-12 is known as macrophage metalloelastase which 
contributes to degradation of extracellular matrix during inflammatory tissue destruction. 
However MMP-12 can be translocated into the nucleus where it binds to the NFKBIA 
promoter, driving transcription [117]. Intracellular MMP-12 mediates NFKBIA 
transcription, leading to IFN-α secretion and host protection from virus-infection. The 
recent findings of nuclear localization of MMPs open new avenue in which MMPs cleave 
and activate intracellular peptides as well as induce specific gene expression.  
 
1.4.5.2. NAG-1 
This will be discussed in Chapter III. 
 
1.5. Summary Conclusion 
The list of multifunctional proteins and their new biological role are continuing to 
grow. Changing subcellular localization contributes to giving proteins additional 
functions that are seen in the proteins described above (Tab. 1.1). Remarkably, disease 
progression may not only arise from gene mutation and expression of splice variants, 
but also through dysregulation of protein sorting system which controls protein 
localization in the cell.  
 
 
 24 
 
Table 1.1 Examples of multifunctional proteins shown in this review. 
Name Primary subcellular 
localization and function 
Additional subcellular localization 
and function 
p53 • Nucleus;  
Transcription factor 
• Mitochondria;  
Promoting mitochondrial membrane 
permeabilization 
Smads • Nucleus; 
Transcription factor 
• Cytoplasm; 
Adaptor protein 
Hsp90 • Cytoplasm; 
Molecular chaperone 
• Extracellular region; 
Regulator for angiogenesis and cell 
invasiveness 
TG2 • Cytoplasm; 
Catalyzes protein cross-linking 
• Nucleus; 
Regulates gene expression 
Extracellular region; 
• Implicates in cell adhesion and 
spreading 
GAPDH • Cytoplasm; 
Glycolytic enzyme 
• Nucleus; 
Participates in gene regulation 
HMGB1 • Nucleus; 
Binds to nucleosomes 
• Extracellular region; 
Inflammatory cytokine 
E-cadherin • Cell surface; 
Plays a role in cell adhesion 
• Nucleus; 
Implicates in gene regulation 
TβRI • Cell surface; 
Type I transmembrane protein 
• Nucleus; 
Participates in gene regulation 
EGFR • Cell surface; 
Membrane receptor tyrosine 
kinase for EGF 
• Nucleus; 
Co-transcription factor 
MMPs • Extracellular region; 
Secretion protein involved in 
proteolysis  
• Nucleus; 
Regulates gene expression 
NAG-1 • Extracellular region; 
Secretion protein involved in 
apoptosis 
• Nucleus; 
Implicates in gene regulation 
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CHAPTER 2 
 
A peroxisome proliferator-activated receptor ligand MCC-555 imparts 
anti-proliferative response in pancreatic cancer cells by PPAR 
gamma-independent up-regulation of KLF4 
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The results discussed in this chapter have been published in Toxicology and Applied 
Phamacology, Volume 263, Issue 2, 1 September 2012, Pages 225–232 
 
2.1 Abstract 
MCC-555 is a novel PPARα/ dual ligand of the thiazolidinedione class and was 
recently developed as an anti-diabetic drug with unique properties. MCC-555 also has 
anti-proliferative activity through growth inhibition and apoptosis induction in several 
cancer cell types. Our group has shown that MCC-555 targets several proteins in 
colorectal tumorigenesis including nonsteroidal anti-inflammatory drug (NSAID)-
activated gene (NAG-1) which plays an important role in chemoprevention responsible 
for chemopreventive compounds.  
NAG-1 is a member of the TGF-β superfamily and is involved in tumor 
progression and development; however, NAG-1’s roles in pancreatic cancer have not 
been studied. In this report, we found that MCC-555 alters not only NAG-1 expression, 
but also p21 and cyclin D1 expression. NAG-1 and p21 expression was not blocked by 
PPAR-specific antagonist GW9662, suggesting that MCC-555-induced NAG-1 and p21 
expression is independent of PPAR activation. However, decreasing cyclin D1 by 
MCC-555 seems to be affected by PPAR activation. Further, we found that the GC box 
located in the NAG-1 promoter play an important role in NAG-1 transactivation by MCC-
555. Subsequently, we screened several transcription factors that may bind to the GC 
box region in the NAG-1 promoter and found that KLF4 potentially binds to this region. 
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Expression of KLF4 precedes NAG-1 and p21 expression in the presence of MCC-555, 
whereas blocking KLF4 expression using specific KLF4 siRNA showed that both NAG-1 
and p21 expression by MCC-555 was blocked. 
 In conclusion, MCC-555’s actions on anti-proliferation involve both PPAR-
dependent and -independent pathways, thereby enhancing anti-tumorigenesis in 
pancreatic cancer cells. 
 
2.2 Introduction 
Pancreatic cancer is a major cause of cancer-related deaths in developed 
countries and has the highest mortality rate among major cancers. Pancreatic cancers 
may cause only vague symptoms before being detected, and chemotherapeutic 
regimens for this disease have provided very limited improvements in tumor regression 
and overall survival rates after diagnosis [118]. Although the precise pathogenesis of 
pancreatic cancer remains unclear, common mutations in several cell proliferation-
related genes have been described: mutation of K-ras, p16, p53, and Smad4 genes has 
been identified in sporadic pancreatic tumors [119].  
The peroxisome proliferator-activated receptors (PPARs) are members of the 
nuclear receptor superfamily and function as ligand-activated transcription factors. 
PPARs function in a variety of roles including cell differentiation, metabolism, immune 
function and cell growth. Thiazolidinediones, synthetic PPAR ligands, are used to treat 
patients with type 2 diabetes, and current studies have shown that thiazolidinediones 
also have anti-tumorigenic activity in a wide variety of cancer cells [120-123]. Intense 
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studies on the role of PPAR ligands in colorectal cancer cells have showed that PPAR 
activation may be implicated in the inhibition of cell proliferation genes and induction of 
apoptosis in colorectal cancer cells [122, 124, 125]; however, effects and molecular 
targets of PPAR ligands in pancreatic cancer cells have not been studied in detail.  
MCC-555 (RWJ-241947) is a novel class of thiazolidinediones and was recently 
established as an anti-diabetic drug in animal models of Type 2 diabetes, and is more 
effective in the anti-diabetic potency compared to other PPAR ligands. Like other 
thiazolidinediones, MCC-555 binds to PPAR and increases transcriptional activities, but 
its binding affinity for PPAR is relatively weak compared to other PPAR-specific 
agonists [126]. MCC-555 effects not only PPAR as effective anti-diabetic agents but 
also PPARα as anti-hyperlipidemic agents [127]. MCC-555 has been reported to be 
over 50-fold more potent than rosiglitazone in decreasing blood glucose levels in rodent 
models of type 2 diabetes and 5- to 10-fold less effective than rosiglitazone in inducing 
adipogenesis in mouse preadipocytes [128, 129]. These effects may be explained by 
the ability of MCC-555 to act as a PPAR agonist, partial agonist, or antagonist, 
depending on cell context [130]. The same scenario may apply to the effect of MCC-555 
on anti-proliferative activity. MCC-555 has an anti-tumorigenic activity against prostate 
cancer [131] and colorectal cancer [126] in both PPAR-dependent and -independent 
manners. It has been shown that dual ligands exhibit better activity with respect to cell 
growth inhibition, compared to the PPAR specific agonists [132], Thus, it is expected 
that dual ligands for PPAR may provide a better outcome to prevent cancer. Since the 
anti-proliferative potency of MCC-555 has not been examined in pancreatic cancer 
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cells, we extended our knowledge to pancreatic cancer to investigate whether MCC-555 
affects anti- cancer activity along with several molecular targets affected in 
tumorigenesis.  
MCC-555 and other PPAR ligands modulate the expression of various genes 
such as NAG-1, p21, cyclin D1, and KLF4 through a PPAR-dependent or -independent 
pathway [125, 133, 134]. We have reported that KLF4 is the key regulator that induces 
NAG-1 by MCC-555 in colorectal cancer cells [135]; however, in this study, we found a 
novel cis-acting element where KLF4 binds to the NAG-1 promoter in pancreatic cancer 
cells. KLF4 is a well-known transcription factor that induces p21 and suppresses cyclin 
D1 [136, 137]; however, KLF4 seems to not be involved in cyclin D1 down-regulation in 
the presence of MCC-555. Therefore, the mechanisms by which MCC-555 induces cell 
growth inhibition may be associated with both PPAR dependence and independence 
and affects multiple targets in pancreatic cancer cells.  
 
2.3 Materials and Methods 
 
2.3.1 Cell lines, reagents, antibodies, and DNA constructs 
Human pancreatic cancer cell lines BxPC3 and AsPC-1 were purchased from 
American Type Culture Collection (Manassas, VA). Both cell types were maintained in 
RPMI1640 medium. The culture media contained 10% fetal bovine serum (Hyclone), 50 
U/ml penicillin and 50 μg/ml streptomycin. MCC-555, ciglitazone, rosiglitazone, 
troglitazone, 15-deoxy-Δ12,14-prostaglandin J2, and GW9662 were purchased from 
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Cayman Chemical Co. (Ann Arbor, MI), and all chemicals were dissolved in 
dimethylsulfoxide (DMSO). Anti-human NAG-1 antibody was previously described [138]. 
Antibodies against KLF4, Sp1, Sp3, ZF9, BTEB1, MAZ, cyclin D1 and actin were 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA), whereas p21 antibody 
was purchased from Cell Signaling Technology (Beverly, MA). The NAG-1 promoter 
constructs pNAG-1-3500/+41, pNAG-1-1086/+41, pNAG-1-474/+41, pNAG-1-133/+41 
and the internal deletion mutant clones derived from pNAG-1-133/+41 were described 
previously [139-141].   
  
2.3.2 Cell proliferation analysis 
Cell proliferation was investigated using the CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (Promega, WI). Cells were plated in a 96-well plate at 1,000 
cells/well in four replicates. Cells were then stimulated with different doses of MCC-555 
in the presence of 1% serum. After two days treatment, 20 μl of CellTiter 96 Aqueous 
One Solution was added to each well, and the plate was incubated for 1 h at 37ºC. 
Absorbance at 490 nm was recorded in an enzyme-linked immunosorbent assay plate 
reader (Bio-Tek Instruments, Winooski, VT). 
 
2.3.3 Caspase 3/7 enzyme activity 
Enzyme activity of caspase 3/7 was analyzed using the Caspase-Glo 3/7 Assay 
kit (Promega) according to the manufacturer’s protocol. Briefly, cells were seeded onto 
a 96-well plate at 5,000 cells/well in four replicates. The cells were then treated with 10 
 31 
 
μM MCC-555 in the absence of serum. After 24 hours, 100 μl of caspase-Glo 3/7 
Reagent was added into each well, and the plate was incubated for 1 hour at room 
temperature. Luminescence was measured using an FLX800 microplate reader (Bio-
Tek). 
 
2.3.4 Cell cycle analysis 
Cells were plated at 4x105 cells/well in 6-well plates, and then treated with MCC-
555 (10 μM) for 24 hours. The cells (attached and floating cells) were then harvested, 
washed with phosphate-buffered saline (PBS), fixed by slow addition of 1 ml cold 70% 
ethanol and stored at -80ºC. The fixed cells were pelleted, washed with 50% and 30% 
ethanol in PBS, and stained with 0.5 ml of 70 μM propidium iodide containing 1 mg/ml 
RNase for 15 min at room temperature. Ten-thousand cells were examined by flow 
cytometry using a Becton Dickinson fluorescence-activated cell sorter equipped with 
CellQuest software, by gating on an area vs. width dot plot to exclude cell debris and 
cell aggregates. 
 
2.3.5 TUNEL assay 
Apoptosis in the BxPC-3 cells was determined by the terminal deoxynucleotidyl 
transferase (TdT)-mediated dUTP–biotin nick end labeling (TUNEL) staining method 
using an in situ cell detection kit (TACS 2 TdT Blue kit, Trevigen, Gaithersburg, MD) 
according to the manufacturer’s instructions. Briefly, the cells on coverslips were fixed 
with 3.7% formaldehyde and permeabilized with proteinase K solution. The slides were 
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then immersed in quenching solution and 1 X terminal deoxynucleotidyl transferase 
(TdT) labeling buffer and incubated in labeling reaction mix containing TdT dNTP mix 
and TdT enzyme. After 1 hour, the cells were immersed in strep-HRP solution for 10 min 
and then were incubated in TACS-blue label solution. The slides were counterstained 
with Nuclear Fast Red solution, and the stained slides were observed and 
photographed using light microscopy. 
 
2.3.6 Western blot analysis 
Western blot analysis was performed as described previously [135]. Briefly, cells 
were starved overnight, and treated with MCC-555 at the indicated time and dose in 
serum-free media. Cell lysates were obtained using RIPA buffer containing protease 
inhibitor cocktail (Calbiochem, San Diego, CA). Protein concentration was determined 
by bicinchoninic acid protein assay (Pierce, Rockford, IL). Proteins were separated on 
SDS/polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes 
(Osmonics, Minnetonka, MN). The membranes were incubated with a specific primary 
anti-serum in tris-buffered saline containing 0.05% Tween 20 (TBS-T) and 5% non-fat 
dry milk at 4ºC overnight. After three washes with TBS-T, the blots were incubated with 
peroxidase conjugated immunoglobulin G for 1 hour at room temperature, visualized 
using ECL (Amersham Biosciences, Piscataway, NJ) and quantified by Scion Image 
Software (Scion Corp., Frederick, MD). 
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2.3.7 Real-Time RT-PCR Analysis 
Total RNA was isolated from BxPC3 and AsPC-1 cells using RNA isolation kit 
(OMEGA Bio-Tek, Norcross, GA), and 1 µg of RNA was reverse-transcribed with an 
iScript cDNA kit (BioRad, Hercules, CA) according to the manufacturer’s instruction. 
PCR was carried out using  Absolute qPCR SYBR Green Mix (Thermo Scientific, UK) 
with primers for human NAG-1, p21, cyclinD1 and GAPDH as follows: NAG-1, forward 
5’-ATGCCCGGGCAAGAACTC-3’ and reverse 5’-CATATGCAGTGGCAGTC-3’; p21, 
forward 5’-GCGACTGTGATGCGCTAAT-3’ and reverse 5’-
TAGGGCTTCCTCTTGGAGAA-3’; cyclin D1, forward 5'-
ATGGAACACCAGCTCCTGTGCTGC-3' and reverse 5'-
TCAGATGTCCACGTCCCGCACGT-3'; GAPDH, forward 5'-GGGCTGCTTTTA ACT 
CTGGT-3' and reverse 5'-TGGCAGGTTTTTCTAGACGG-3'. 
Gene expression levels were calculated and GAPDH was used as a control gene, using 
MyiQ thermal cycler (Bio-RAD). Vehicle-treated samples were set to 1 and fold change 
are represented as mean ± S.D. 
 
2.3.8 Transient transfection and luciferase reporter assays 
BxPC3 cells were plated in 12-well plates at 2 x 105 cells/well. The next day, 
plasmid mixtures containing 0.5 μg of NAG-1 promoter linked to luciferase and 0.05 μg 
of pRL-null vector were transfected by PolyJet transfection reagent (Signagen, 
Rockville, MD) according to the manufacturer’s protocol. After transfection, cells were 
treated with DMSO or MCC-555 (10 μM) in serum-free media for 24 hours. Cells were 
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harvested in 1 x passive lysis buffer (Promega), and luciferase activity was measured 
using DualGlo Luciferase Assay Kit (Promega). The results were normalized to pRL-null 
luciferase activity.  
 
2.3.9 RNA interference 
Klf4 siRNA was purchased from Santa Cruz Biotechology and control siRNA was 
purchased from Ambion. BxPC-3 cells were transfected with 10 μM of KLF4 or control 
siRNA using PepMute siRNA Transfection reagent (Signagen), according to the 
manufacturer’s protocol. After transfection for 24 hours, cells were serum starved 
overnight and treated as indicated. Total protein was subjected to Western blot analysis 
as described.  
 
2.3.10 Chromatin immunoprecipitation 
Cells were fixed with 1% formaldehyde for 10 minutes at 37ºC and sonicated four 
times for 10 seconds. Cell lysates (0.2 ml) were diluted with 0.8 ml of 
immunoprecipitation buffer (0.1 % SDS, 1 % Triton X-100, 0.1 % Na-deoxycholate and 
140 mM NaCl) and immunoprecipitated with 10 μg specific antibodies for normal IgG or 
KLF4 at 4ºC overnight. The chromatin-associated DNA was eluted, reverse cross-linked 
by heating at 65ºC for 4 hours and treated with proteinase K at 45ºC for 2 hours. DNA 
was purified by phenol/choloroform extraction, and precipitated DNA was amplified 
using the following primer pairs: forward 5’- CCAGAAATGTGCCCTAGCTT-3’ and 
reverse 5’-GAGCTGGGACTGACCAGATG-3’. PCR products (202 bp) were resolved on 
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2% agarose gel and visualized under UV light.  
 
2.3.11 Statistical analysis 
SAS for windows (v9.2; SAS institute, Inc.) statistical analysis software was used. 
For multiple group comparisons, analysis of variance with Tukey’s multiple comparison 
test was used to compare mean values. The Student t test was used to analyze 
differences between samples. Results were considered statistically significant at * P < 
0.05, ** P < 0.01, and *** P < 0.001. 
 
2.4 Results 
 
2.4.1 MCC-555 induces cell growth arrest and apoptosis in pancreatic 
cancer cells  
The effects of PPAR agonists on cancer are mediated in PPAR-dependent 
and/or -independent manners, depending on cell types or ligand structures [142]. In this 
study, we have investigated the therapeutic properties of MCC-555 in human pancreatic 
adenocarcinoma cells. BxPC-3 cells were treated with MCC-555 for 2 days, and we 
observed the reduction of cell proliferation in MCC-555 treated cells in a dose 
dependent manner, compared to DMSO-treated cells (Fig. 2.1A). To investigate whether 
MCC-555 arrests cell cycle, we stained cells with propidium iodide and examined cell 
cycle status. Treatment with MCC-555 resulted in a significant increase in cells arrested  
at the G1 phase (Fig. 2.1B), consistent with previous reports that PPAR ligands arrest  
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Figure 2.1 MCC-555 inhibits cell proliferation and induces apoptosis in human 
pancreatic cancer cells. 
A, BxPC-3 cells were treated with vehicle or MCC-555 in a dose depedent manner. 
Cell growth was measured using the CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay. Values are expressed as mean ± S.D. of four replicates. P < 
0.01** and P < 0.001***, compared to vehicle-treated cells. B, Flow cytometric 
analysis of vehicle- or MCC-555-treated BxPC-3 cells. Cell were treated with vehicle 
or MCC-555 for 24 h and stained with propidium iodide as decribed in Materials and 
Methods. Percentage of G1 is expressed as mean ± S.D of three replicates. P < 
0.01**. C, Caspase 3/7 enzymatic activity was measured as described in Materials 
and Methods. BxPC-3 cells were pretreated with either vehicle or caspase inhibitor 
(10 μM, Z-VAD-FMK) for 30 min, and then were stimulated with MCC-555. Values 
are expressed as mean ± S.D of three replicates. P < 0.001***. D, Apoptosis was 
analyzed by TUNEL assay using BxPC-3 cells treated with 10 μM MCC-555 for 24 h 
(40X). The graph indicates the percentage of MCC-555-treated cells versus the 
vehicle-treated cells from the reading of three randomly defined areas. P < 0.05*.  
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cell cycle at the G1 phase in other cells [143, 144]. To examine whether MCC-555 
affects apoptosis of human pancreatic cancer cells, we performed caspase 3/7 activity 
and TUNEL assay using BxPC-3 cells treated with either DMSO or MCC-555 (10 µM). 
As shown in Fig. 2.1C, MCC-555 treatment significantly increased caspase 3/7 activity, 
and addition of caspase inhibitor with MCC-555 resulted in decreasing caspase 3/7 
activity, indicating that MCC-555-induced apoptosis is mediated by caspase 3/7 activity. 
We also performed TUNEL assay to detect apoptotic cells in the presence of MCC-555. 
As shown in Fig. 2.1D, MCC-555 enhanced TUNEL positive cells in MCC-555-treated 
cells, compared to vehicle-treated cells. Taken together, MCC-555 seems to increase 
cell cycle arrest and apoptosis in pancreatic cancer cells; these results appear to 
account for the cell growth arrest as seen in Fig. 2.1A.    
 
2.4.2 MCC-555 induces NAG-1 and p21, and suppresses cyclin D1 
expression 
To elucidate the molecular mechanism(s) by which MCC-555 induces cell cycle 
arrest and apoptosis in human pancreatic cancer cells, we analyzed the expression of 
pro-apoptotic gene NAG-1, and cell cycle regulators p21 and cyclin D1. It has been 
reported that several PPAR agonists induce NAG-1 expression, which exerts anti- 
cancer activity in colorectal cancer cells [124, 145]. Likewise, expression of cyclin D1, 
and p21 are altered in the presence of PPAR ligands [146, 147]. BxPC-3 cells were 
treated with several PPAR agonists, including MCC-555, rosiglitazone (RGZ), 15- 
deoxy-Δ12,14-prostaglandin J2 (PGJ2), and troglitazone (TGZ). MCC-555 and TGZ  
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Figure 2.2 MCC-555 induces NAG-1 and p21, and suppresses cyclin D1 
expression. 
A, BxPC-3 cells were treated with DMSO or 10 μM of various PPAR ligands for 24 
h, and Western blot was performed with antibodies for NAG-1, p21, Cyclin D1 and 
Actin. B, C, BxPC-3 and AsPC-1 cells were treated with 10 μM of MCC-555 at the 
indicated times and were treated with the indicated doses for 24 h. Western blot was 
performed with antibodies for NAG-1, p21, Cyclin D1 and Actin. N.S., non-specific. 
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dramatically induced NAG-1 expression compared to other PPAR agonists. MCC-555 
and TGZ also induced p21 as well as suppressed cyclin D1 expression (Fig. 2.2A). In 
this report, we focus on MCC-555’s effects since TGZ was withdrawn from the market 
due to the prevalence of adverse liver effects [148]. NAG-1 and p21 were induced by 
MCC-555 not only in BxPC-3 cells, but also in other pancreatic cancer cells AsPC-1 in a 
dose- and time-dependent manner, whereas cyclin D1 was suppressed by MCC-555 in 
both cells in a dose- and time-dependent manner (Fig. 2.2B and C). Long-term 
treatment (48 h) of MCC-555 exhibits the reduction of p21 protein in both cell lines, 
probably due to cytopathic effects. 
 
2.4.3 Cyclin D1, but not NAG-1 and p21 expression is involved in PPARγ 
activation  
We examined whether NAG-1, p21 and cyclin D1 expression by MCC-555 is 
regulated by PPAR transcription factor activation. First, qRT-PCR results showed that 
these transcripts were dose-dependently altered by MCC-555 in BxPC-3 and AsPC-1 
cells (Fig. 2.3A). It has been reported that BxPC-3 and AsPC-1 cells express PPAR 
and treatment with PPAR agonists induces apoptosis and differentiation in these cells 
[149, 150]. To determine whether NAG-1, p21 and cyclin D1 expression by MCC-555 is 
dependent on PPAR activation, PPAR antagonist GW9662 was used to treat the cells. 
As shown in Fig. 2.3B, NAG-1 and p21 induction by MCC-555 were not blocked by 
GW9662 treatment, but reduction of cyclin D1 by MCC-555 was inhibited by GW9662  
 40 
 
 
Figure 2.3 Cyclin D1, but not NAG-1 and p21, expression is involved in PPARγ 
activation.  
A, Total RNAs were isolated from BxPC-3 and AsPC-1 cells after MCC-555 
treatment. The expression of transcripts for NAG-1, p21 and Cyclin D1 was analyzed 
by qRT-PCR, normalized to GAPDH. Fold change compared to vehicle-treated cells 
are represented, vehicle-treated cells are set as 1. Error bars represent the 
mean±S.D of three replicates. B, Effects of PPARγ antagonist on MCC-555-induced 
NAG-1 and p21 up-regulation, and MCC-555-induced Cyclin D1 down-regulation. 
BxPC-3 cells were pretreated with GW9662 for 30 min at the indicated dose and 
then the cells were treated with 10 μM of MCC-555 for 24 h. Total proteins were 
isolated for Western blot analysis. Equal loading was confirmed by Actin.  
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treatment, indicating that NAG-1 and p21 induction by MCC-555 is independent of 
PPARactivation, whereas cyclin D1 suppression by MCC-555 is dependent on PPAR 
activation.  
 
2.4.4 The GC box region in -133/+41 NAG-1 promoter is responsible for 
NAG-1 transactivation  
Unlike cyclin D1 and p21 regulation by PPARγ ligands, NAG-1 expression by 
PPAR ligands in pancreatic cancer cells has not been studied in detail. Therefore, we 
decided to further examine the transcriptional regulation of NAG-1 affected by MCC-
555. BxPC-3 cells were transfected with the four serial deletion constructs of the human 
NAG-1 promoter, and then were treated with MCC-555. Treatment with MCC-555 
resulted in increasing the promoter activity in all of the constructs tested (Fig. 2.4A). 
Therefore, the -133/+41 promoter region was further analyzed using the TFSEARCH 
site (http://www.cbrc.jp/research/db/TFSEARCH.html) and TESS 
(http://www.cbil.upenn.edu/cgi-bin/tess/tess33?RQ=SEA-FR-Query). There are several 
cis-acting elements in this region including activating transcription factor 3 (ATF3), MYC-
associated zinc finger protein (MAZ), retinoic acid receptor α (RAR-α), xenobiotic 
response element binding factor (XF-1) and specificity protein 1 (Sp1) binding sites. To 
investigate the responsible site in MCC-555-mediated transcriptional regulation of NAG-
1, we used internal deletion clones in which the aforementioned transcription binding 
sites were deleted. As shown in Fig. 2.4B, transfection with a double deletion clone 
lacking the two potential Sp1 binding sites (or GC box) significantly attenuated MCC- 
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Figure 2.4 Identification of the cis-acting elements responsible for MCC-555-
induced NAG-1 transactivation.  
A, Indicated constructs of the NAG-1 promoter (0.5 µg) and pRL-null (0.05 µg) were 
transfected into BxPC-3 cells for overnight. The transfected cells were exposed to 
MCC-555 for 24 h. The promoter activity was measured as a ratio of firefly luciferase 
activity/Renilla luciferase activity. The results are the mean ± S.D of three replicates. 
P < 0.05* and P <0.01**, compared to DMSO treated sample. RLU, relative 
luciferase unit. B, BxPC-3 cells were transfected with each internal deletion construct 
of -133/+41 NAG-1 and then treated with vehicle or 10 μM MCC-555 for 24 h. The x-
axis shows fold induction relative to vehicle-treated samples. Data were analyzed 
using Tukey’s multiple comparison test; mean with same letters indicate no 
significance (P < 0.05).    
 
 43 
 
555-induced promoter activity, compared to wild-type promoter, suggesting that these 
two GC box sites are important in MCC-555-induced NAG-1 expression in pancreatic 
cancer cells.   
 
2.4.5 KLF4 is a key molecule to regulate MCC-555-induced NAG-1 and p21 
expression 
To determine what trans-acting elements are involved in these GC boxes, we 
decided to examine the expression of proteins that could bind to these sites. Sp or 
several Sp-related transcriptional factors could bind to these GC boxes. The results 
indicate that expression of Sp transcription factors (Sp1 and Sp3) was not altered; only 
KLF4 was increased by MCC-555 in a dose-dependent manner, implying that KLF4 
expression by MCC-555 could be responsible for NAG-1 expression in human 
pancreatic cancer cells (Fig. 2.5A). This is consistent with the previous report, indicating 
that MCC-555 increases KLF4 expression in human colorectal cancer cells [135]. Other 
zinc-finger proteins including ZF9 and MYC-associated zinc finger protein (MAZ) were 
marginally expressed in pancreatic cancer cells, whereas basic transcription element-
binding protein 1 (BTEB1) was highly expressed; however, MCC-555 does not affect 
their expression. If KLF4 regulates NAG-1 expression in responding to MCC-555, KLF4 
expression should be an earlier event than NAG-1 expression. As shown in Fig. 2.5B, 
KLF4 expression preceded NAG-1 expression in the presence of MCC-555. To confirm 
KLF4’s role in MCC-555-induced NAG-1 expression, specific KLF4 siRNA was utilized. 
The results clearly indicate that blocking KLF4 expression resulted in the reduction of 
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NAG-1 and p21 expression (Fig. 2.5C). Interestingly, blocking KLF4 expression did not 
affect MCC-555-induced cyclin D1 suppression, suggesting that KLF4 expression may 
not be involved in MCC-555-induced cyclin D1 suppression. Finally, a ChIP assay was 
performed to confirm that KLF4 binds to the NAG-1 promoter in responding to MCC-555 
(Fig. 2.5D).   
 
2.5 Discussion 
Pancreatic cancer is the fourth leading cause of cancer deaths, and the survival 
rate is very poor compared to other cancers. Since conventional therapeutic 
approaches do not decrease the incidence of mortality of this deadly cancer, we have 
paid more attention to alternative research including identification of molecular target 
approaches for an increasing survival rate.   
The PPARγ agonists affect cell proliferation, differentiation, and apoptosis in a 
PPAR-dependent and/or -independent manner, and thereby represent a potentially 
important family of therapeutic compounds for cancer treatment. Many studies describe 
the beneficial effects of the PPAR agonists for treatment of lung [151], ovarian [152], 
breast [153] and colorectal [124] cancers in vitro and in vivo. Recently, clinical success 
in cancer prevention research and diabetic treatment with PPARγ agonists was 
overshadowed by reports of several side effects that include obesity, cardiotoxicity, and 
liver toxicity [154]. However, Choi et al., reported CDK5 is a new molecular target of the 
PPARγ ligand [155], and this finding could reverse the negative swing of the PPARγ 
ligand in diabetic research. As a similar token, identification of novel targets induced by  
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Figure 2.5 MCC-555-induced KLF4 is responsible for NAG-1 and p21 
expression.  
A, B, BxPC-3 cells were treated with MCC-555 at indicated time and dose. Protein 
lysates were harvested and subjected to Western blot analysis using KLF4, Sp1, 
Sp3, Zf9, BTEB1, MAZ, NAG-1, and Actin antibodies. C, BxPC-3 cells were 
transfected with either control or KLF4 siRNA using PepMute siRNA Transfection 
reagent according to the manufacturer’s protocol. Cells were serum starved 
overnight and treated with DMSO or MCC-555 for 24 h, followed by Western 
analysis. D, Chromatin immunoprecipitation assay was performed using a DNA-
protein complex treated with 10 μM MCC-555 for 6 h as described in Materials and 
Methods. The Sp1 binding sites of the human NAG-1 promoter (-133/+41) were 
amplified by PCR primer pairs (arrows). The input represents PCR products obtained 
from 1% aliquots of chromatin pellets before immunoprecipitation. 
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PPARγ ligands in cancer research may help to promote their potential use. Dual ligands 
for PPARα and PPARγ, such as MCC-555, alternatively have been developed to 
improve treatment of metabolic syndrome, including hyperglycemia and hyperlipidemia. 
These dual ligands also possess anti-proliferative activities against a variety of cancer 
cell lines [125, 126] with greater potency than conventional PPARγ-specific ligands. In 
this report, we used MCC-555 as a PPAR dual ligand and investigated a new molecular 
target: p21, NAG-1, cyclin D1 and KLF4 in pancreatic cancer cells.  
The biological activity of KLF4 in tumorigenesis is controversial. KLF4 is 
increased in human mammary tumors [156] and oral squamous-cell carcinomas [157], 
suggesting that overexpression of KLF4 may contribute to tumorigenesis. Conversely, it 
has been shown that KLF4 is down-regulated during tumorigenesis of the 
gastrointestinal epithelium [158] and is frequently lost in other human cancer types 
[159]. Consistent with a tumor suppressor function of KLF4 in colon cancer [160], its 
overexpression reduces tumorigenesis in pancreatic cancer cells in vivo [161]. 
Moreover, it has been shown that KLF4 inhibits metastasis of several cancers, including 
pancreatic cancer [162]. Thus, KLF4 may play an important role in pancreas as an anti-
tumorigenic protein, but its exact function may be dependent on cell context. Our data 
support KLF4’s anti-proliferative role in this report, showing that KLF4 controls cell cycle 
inhibitor p21 and pro-apoptotic protein NAG-1.  
A study showed that some PPAR or PPARα/γ agonists regulate the Klf4 mRNA 
expression in PPARγ-dependent or independent manner, providing KLF4 as a novel 
anti-proliferative target of PPARγ ligands in pancreas [163]. From our results, we 
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identified that MCC-555 affects cyclin D1 expression in a PPARγ-dependent manner; 
however, KLF4 seems to be regulated by MCC-555 in a PPAR independent manner 
(Supplementary Fig. S2.1). Our data also support the view that KLF4 is a key protein 
that controls cell cycle regulator p21 and pro-apoptotic protein NAG-1 in the presence of 
MCC-555. We showed that MCC-555 increased KLF4 expression, which results in an 
increased expression of p21 and NAG-1 expression. This view is in agreement with 
reports showing that p21 and NAG-1 are the targets of KLF4 in other cancer cells [135, 
164]. Interestingly, it has been known that KLF4 regulates cyclin D1 expression, but our 
data clearly suggest that KLF4 is not involved in cyclin D1 regulation in the presence of 
MCC-555. It remains unclear, but MCC-555 may affect the modification of KLF4, 
thereby not binding to the cyclin D1 promoter. Alternatively, MCC-555 has been shown 
to activate ERK and other kinases [125], and KLF4 could be phosphorylated by these 
kinases [165], rendering KLF4 activity in cyclin D1 transcriptional regulation. Another 
possible explanation is KLF4 acetylation. Since KLF4 is acetylated by p300, thereby 
controlling its activity [166], MCC-555 may affect KLF4 post-translational modification by 
acetylation, affecting cyclin D1 expression. Finally, PPARγ activation may control more 
effectively than KLF4 activity in the presence of MCC-555; however, the detail 
mechanism needs to be elucidated.  
We have shown that NAG-1 transgenic mice exhibit resistance to carcinogenic-
induced colon and lung adenomas [167, 168], and NAG-1 expression is induced by 
many cancer chemopreventive compounds [139, 169], indicating that NAG-1 possesses 
cancer preventive activity and its induction is beneficial. Therefore, NAG-1 expression 
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induced by MCC-555 may explain the chemopreventive activity of MCC-555 in 
pancreatic cancer.  
 
2.6 Summary Conclusion 
In summary, our data suggest that KLF4 is an upstream molecule that controls 
NAG-1 and p21 expression by MCC-555 at the transcriptional level, along with the 
suppression of cyclin D1 by MCC-555. KLF4/NAG-1 and KLF4/p21 affected by MCC-
555 are mediated in a PPARγ-independent manner, whereas cyclin D1 suppression by 
MCC-555 is mediated in a PPARγ-dependent manner (Fig. 2.6).   
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Figure 2.6 Schematic diagram of cell growth inhibition induced by MCC-555 in 
human pancreatic cancer cells.  
MCC-555 inhibits cell growth via multiple pathways. In addition to Cyclin D1 down-
regulation via the PPAR-dependent pathway, KLF4 is up-regulated via the PPAR-
independent pathway that is responsible for the MCC-555-induced NAG-1 and p21 
expression, leading to cell growth inhibition in human pancreatic cancer cells.   
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CHAPTER 3 
 
NAG-1/GDF15 Accumulates in the nucleus and modulates 
transcriptional regulation of the Smad pathway 
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3.1 Abstract 
Protein dynamics, modifications, and trafficking are all processes that can 
modulate protein activity. Accumulating evidence strongly suggests that many proteins 
play distinctive roles dependent on cellular location. Nonsteroidal anti-inflammatory drug 
activated gene-1 (NAG-1) is a TGF-β superfamily protein that plays a role in cancer, 
obesity, and inflammation. NAG-1 is synthesized and cleaved into a mature peptide, 
which is ultimately secreted into the extracellular matrix (ECM). In this study, we have 
found that full-length NAG-1 is expressed in not only the cytoplasm and ECM, but also 
in the nucleus. NAG-1 is dynamically moved to the nucleus, exported into cytoplasm, 
and further transported into the ECM. We have also found that nuclear NAG-1 
contributes to inhibition of the Smad pathway by interrupting the Smad complex. 
Overall, our study indicates that NAG-1 is localized in the nucleus and provides new 
evidence that NAG-1 controls transcriptional regulation in the Smad pathway.   
 
3.2 Introduction 
The study of genes altered by anti-cancer compounds has great value in regard 
to cancer chemoprevention and therapeutics. Building on this research, we identified 
the non-steroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) as a 
divergent member of the TGF-β superfamily [138]. NAG-1 has also been identified by 
other groups using a variety of different cloning strategies and has been called growth 
differentiation factor 15 (GDF15) [170], placental transformation growth factor-β 
(PTGFB) [171], macrophage inhibitory cytokine-1 (MIC-1) [172], prostate-derived factor 
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(PDF) [173], and placental bone morphogenetic protein (PLAB) [174]. Research to date 
has demonstrated that NAG-1 is able to be induced not only by NSAIDs [175], but also 
by chemopreventive dietary compounds [169, 176-179] and PPAR ligands [124, 125, 
145, 180]. These compounds affect NAG-1 induction via the tumor suppressor genes 
p53, early growth response-1 (EGR-1), and/or via the PI3K/AKT/GSK-3 pathway [120, 
124, 181, 182]. Unlike the transcriptional regulation of NAG-1, the principal function, 
receptor, and signaling pathway of NAG-1 remain uncertain, and the biological role of 
NAG-1 in tumorigenesis remains poorly understood and sometimes contradictory. For 
example, NAG-1 plays a role in cancer development and progression, but various 
results show it acting as either a pro-tumorigenic or anti-tumorigenic protein [183]. NAG-
1 also controls stress responses, bone formation, hematopoietic development, and 
adipose tissue function, as well as contributing to cardiovascular diseases [184-186].  
A transgenic mouse was developed in the authors’ laboratory that ubiquitously 
over-expresses the human NAG-1 gene [167]. These mice are resistant to chemical- 
and genetic-induced cancers and have a decreased systemic inflammatory response 
[167, 184, 187]. Furthermore, the transgenic mice weigh less and have less fat, despite 
similar food intake as wild-type (WT) littermates, suggesting NAG-1 may act to alter 
metabolism, as well [167]. Recently, we reported that NAG-1 modulates metabolic 
activity by increasing the expression of key thermogenic and lipolytic genes in adipose 
tissue [188]. That study suggested that NAG-1 is also a novel therapeutic target in 
preventing and treating obesity and insulin resistance.    
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NAG-1 is synthesized as a 308-amino acid pro-NAG-1 monomer and then 
dimerizes by a specific disulfide linkage. The pro-NAG-1 dimer is then cleaved by furin-
like proteases at an RXXR site, forming a 112 amino acid C-terminal dimeric protein 
and pro-peptide.[183] This mature dimeric protein is secreted in the ECM, and can be 
detected in the blood of humans. Some evidence suggests the pro-NAG-1 dimer binds 
to the ECM and contributes to latent storage in the stroma [189], but the fate and role of 
pro-NAG-1 is poorly understood. Experimental evidence clearly confirms the secreted 
mature dimer has biological activity [188]; however, the multiple forms of NAG-1 present 
in the cells, their interaction with the cellular system, and their biological activity is 
unclear. Therefore, there is clearly a need for further study of the molecular 
mechanisms by which pro-NAG-1 contributes to NAG-1’s biological activity.  
A number of studies suggest that secreted proteins can localize in the nucleus 
and exhibit distinctive activity [7, 117]. For example, secreted proteins bFGF and 
odontogenic ameloblast-associated protein (ODAM) are expressed in the nucleus and 
cytoplasm, as well as the ECM [190]. Thus, a secreted protein like NAG-1 could also 
localize and alter molecular events within the nucleus.  In this report, we tested this 
hypothesis and show the trans-localization of pro-NAG-1 into the nucleus followed by its 
exportation by CRM1. Our results suggest that the cleavage of pro-NAG-1 to the mature 
form and its subsequent secretion is dependent on translocation into the nucleus. The 
pro-NAG-1 inside the nucleus altered gene expression and interfered with the TGF-β1-
induced Smad signaling pathway, thereby altering cell migration. This is the first study 
demonstrating the critical importance of NAG-1 nuclear translocation in secretion of the 
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mature dimer and the first report confirming a biological activity for pro-NAG-1 in the 
nucleus. 
 
3.3 Materials and Methods 
 
3.3.1 Cell culture and reagents  
U2OS and HCT-116 were cultured in McCoy’s 5A supplemented with 10% FBS 
(Hyclone) and 1% penicillin/streptomycin (Lonza). HEK293 cells were cultured in 
Dulbecco's modified Eagle’s medium (DMEM) with 10% FBS and 1% 
penicillin/streptomycin. The NAG-1 tetracycline-inducible U2OS cell line has been 
described previously.[191] All cultured cells were maintained at 37°C in humid 
conditions with 5% CO2. The following antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA): anti-V5 (sc-271944), anti-CRM1 (sc-5595), anti-
tubulin α (sc-8035), anti-lamin A/C (sc-6215), anti-histone H1 (sc-10806), anti-β-actin 
(sc-47778) and anti-GFP (sc-9996). Anti-Smad2 (#5339), anti-phosphor-smad2 
(#3108), anti-smad2/3 (#8685), anti-smad4 (#9515), anti-p21 (#2947), anti-snail 
(#3879), anti-slug (#9585), anti-hsp90 (#4877) and anti-calnexin (#2679) were 
purchased from Cell Signaling (Danvers, MA, USA). Recombinant human TGF-β1 
(#8915) was also purchased from Cell Signaling. CRM1 inhibitor (leptomycin B, L-6100) 
was from LC Laboratories (Woburn, MA, USA).  
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3.3.2 DNA Constructs and transfection 
Full-length NAG-1 PCR product amplified from pcDNA3/NAG-1[138] was sub-
cloned into pcDNA3.1/V5/His-TOPO vector (Invitrogen, Carlsbad, CA, USA) and 
pcDNA3.1/CT-GFP-TOPO vector (Invitrogen) to generate the V5/His- and GFP-tagged 
clones, respectively. All mutant constructs were generated from pNAG1-V5/His or 
pNAG1-GFP using the QuickChange II site-directed Mutagenesis Kit (Stratagene, Santa 
Clara, CA, USA). PCR primer sequences are described in Supplementary Table 1, and 
all DNA constructs used were verified by DNA sequencing. Transient transfections were 
carried out using either PolyJet (SignaGen, Gaithersburg, MD, USA) or TransIT-2020 
transfection reagent (Mirus Bio, Madison, WI, USA) according to the manufacturer’s 
protocol. 
 
3.3.3 Luciferase assay 
Cells were seeded on a 12-well plated at a density of 1.0 x 105 cells/well. TGF-
β1-inducible reporter constructs p3TP-luc, pPAI-800-luc (SERPINE1 promoter), and 
pSBE4-luc were each co-transfected with pRL-null vector. After 24 h transfection, cells 
were stimulated with TGF-β1 for 24 h in serum-free conditions, and then were harvested 
in 1 x passive lysis buffer (Promega, Madison, WI, USA). Luciferase activity was 
examined using a DualGlo Luciferase Assay Kit (Promega), and data were normalized 
by pRL-null luciferase activity. 
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3.3.4 Subcellular fractionation and immunofluorescence 
For subcellular fractionation, either a Nuclear Extract Kit (Active Motif, Carlsbad, 
CA, USA) or Subcellular Protein Fractionation Kit (Thermo Scientific, Waltham, MA, 
USA) was used according to the manufacturer’s protocol. Proteins for each fraction 
were subjected to Western blot analysis. For immunofluorescence, cells were plated on 
a glass bottom culture dish (MatTek, Ashland, MA, USA). After transient transfection, 
cells were washed twice with phosphate-buffered saline (PBS) and fixed with 4% 
paraformaldehyde for 15 min. After two PBS washes, cells were permeabilized with 
PBS containing 0.25% Triton X-100 for 10 min, followed by incubating with 1% bovine 
serum albumin in PBS for 30 min to block non-specific binding of the antibodies. The 
cells were incubated with diluted primary antibody overnight followed by incubation with 
FITC-conjugated secondary antibody (610-602-002, Rockland Immunochemicals, 
Gilbertsville, PA, USA) for 1 h in the dark. After counterstaining with DAPI, fluorescence 
was observed at 400 x magnification, with digital enlargement when required. 
 
3.3.5 Western blot and immunoprecipitation 
For Western blot, reduced protein samples lysed by RIPA buffer were separated 
on 8% or 10% SDS-PAGE gels, and transferred to nitrocellulose membranes 
(Osmonics). The membranes were incubated with a specific primary antibody in TBS 
containing 0.05% Tween 20 (TSB-T) and 5% nonfat dry milk at 4°C overnight. After 
three washes with TBS-T, the blots were incubated with horseradish peroxidase-
conjugated IgG for 1 h at room temperature, visualized using detection reagent (Thermo 
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Scientific), and quantified by Scion Image Software (Scion Corp.). To conduct 
immunoprecipitation analysis, 1 mg of cell extract lysed by modified RIPA buffer (25 mM 
Tris-Cl pH7.4, 150 mM NaCl, 1 % NP-40, and 5 % glycerol) was incubated with 2 μg 
primary antibody for 2 h at 4°C on a rotating platform, followed by adding protein A/G 
PLUS-agarose (Santa Cruz) overnight. Immunoprecipitation was collected by centrifuge 
at 1000xg for 3 min. After washing five times with modified RIPA buffer, the pellets were 
resuspended with 50 μL 2XSDS-PAGE sample loading buffer and heated at 95°C for 5 
min. Western blot analysis was conducted as described above using 20 μL of the 
immunoprecipitated samples. 
 
3.3.6 In vitro nuclear import assay 
HCT-116 cells were plated on glass coverslips 24 h prior to use. The cells were 
rinsed three times with transport buffer (TB; 20 mM HEPES, pH 7.3, 110 mM potassium 
acetate, 2 mM magnesium acetate), and permeabilized for 5 min with complete TB 
containing 1 mM EGTA, 2 mM DTT, 1 mM PMSF, protease inhibitor cocktail, and 30 
μg/mL digitonin on ice. After two washes with TB, the permeabilized cells were 
incubated in complete TB with HCT-116 cytosol extract, the appropriate GFP-tagged 
NAG-1 expressed in in vitro TNT Quick Coupled Transcription/Translation Systems 
(Promega), and an ATP regeneration system (0.5 mM ATP and GTP, 5 mM creatine 
phosphate, and 50 μg/mL creatine kinase). Assays in the absence of an energy-
regenerating system were conducted with TB without the ATP regeneration system. For 
WGA treatments, permeabilized cells were incubated in the presence of 0.05 mg/mL 
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WGA in TB for 15 min prior to the import reaction. After the import assay, cells were 
fixed with 4% paraformaldehyde, and fluorescent proteins were analyzed by 
immunofluorescence assay. 
 
3.3.7 Library preparation and next generation sequencing (NGS) 
Inducible U2OS cells were grown in the presence or absence of tetracycline (2 
μg/mL) for 2 days. Total RNAs were isolated using E.Z.N.A Total RNA Kit (Omega Bio-
Tek, Norcross, GA, USA) following the manufacturer’s protocol. An Illumina TruSeq 
RNA kit (V2; San Diego, CA, USA) was used for library preparation of mRNA-Seq 
according to the vendor’s instruction. Briefly, (poly A+) mRNAs were purified from 1 μg 
total RNA using poly-T magnetic beads. Messenger RNAs were fragmented to desired 
lengths by incubating at an elevated temperature (94°C) for 8 min in the presence of 
metal ions.  The RNAs were used as templates for the syntheses of the first- and 
second-strand cDNAs, which were subsequently subjected to end repair, A-tailing at 3’ 
ends, adapter ligation, and 15-cycle PCR amplifications. During PCR, individual 
barcodes were incorporated into respective samples to enable sample pooling in 
subsequent DNA sequencing. Paired-end 100-cycle sequencing of the prepared RNA-
Seq libraries were performed on an Illumina HiSeq 2500, following standard protocols of 
the manufacturer. 
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3.3.8 NGS Data analysis 
Sequence reads were processed using the Tuxedo suite (Baltimore, MD, 
USA).[192] Briefly, fastq files were aligned to the UCSC human reference genome 
(hg19) using the TopHat v.2.0.6 software program. The aligned reads were then 
assembled by Cufflinks v.2.0.2 to produce individual transcripts, followed by Cuffmerge 
to integrate the reference human genome annotation (GTF transcription annotations 
from Illumina iGenomes).  The output files were then passed onto the Cuffdiff program 
to create differential expression results. 
 
3.3.9 Real-time qRT-PCR 
Total RNA was isolated using an E.Z.N.A Total RNA Kit (Omega Bio-Tek) 
according to the manufacturer’s protocol. Complementary DNA was made from 1 μg 
isolated RNA using a Verso cDNA synthesis kit (Thermo Scientific) according to the 
manufacturer’s protocol. PCR was carried out using iTaq Universal SYBR Green 
Supermix (Bio-Rad, Hercules, CA, USA). Primers used for qRT-PCR are provided in 
Supplementary Table 3. Relative quantities of mRNAs were calculated using the ΔΔCt 
method and normalized using human Ribosomal Protein, Large, P0 (RPLP0) as an 
endogenous control.   
 
3.3.10 Scratch and transwell migration assay 
For the scratch migration assay, inducible U2OS cells were plated onto a 6-well 
plate and cultured to near (> 90%) confluence. Cells were serum starved for 24 h in the 
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presence or absence of 2 μg/mL tetracycline, and the monolayer was scratched with a 
sterile 10 μL-pipette tip. Then serum-free media containing 10 ng/mL of TGF-β1 was 
added for 24 h.  Phase-contrast images were acquired at 0 and 24 h after the gaps were 
created. The cells migrated into the gaps were counted from three different gap regions. 
For the transwell migration assay, transfected U2OS cells were resuspended in serum-
free medium, and the cell suspension (4 x 104 cells) was added to the upper transwell 
chamber (pore size of 8 μM; Costar; Corning, Corning, NY, USA). Media containing 
0.1% serum and TGF-β1 was added to the bottom wells of the chambers. Cells were 
incubated for 18 h at 37°C, fixed with 4% paraformaldehyde, and permeabilized by 
100% methanol. Cells were then stained with 0.5% crystal violet dissolved in 20% 
methanol at room temperature for 15 min. Cells that had not migrated after 18 h were 
removed from the upper face of the filters using cotton swabs. Migrated cells were 
counted under a light microscope. Images of three different fields were taken for each 
membrane.  
 
3.3.11 3D spheroid invasion assay 
A 96-well 3D spheroid BME cell invasion assay kit (Cultrex) was used according 
to the manufacturer’s protocol with minor modification. Briefly, 2,000 cells were 
resuspended in serum-free media containing spheroid formation ECM. The cells were 
added to a 96-well ultralow attachment round bottom plate, and then incubated for 1 day 
to allow cells to assemble into compact spheroids. Invasion matrix was added to each 
well, and then the cells were incubated for 1 h prior to adding serum-free media 
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containing 10 ng/mL TGF-β1. The plate was incubated for 2 days, and spheroids were 
photographed at 8 x magnification.  
 
3.3.12 DNA pull-down assay 
Tetracycline-treated or non-tetracycline-treated inducible U2OS cells grown on a 
10-cm dish were stimulated with or without 5 ng/mL of TGF-β1 for 2 h. Whole cell 
lysates were prepared in lysis buffer (10 mM HEPES pH 7.5, 150 mM NaCl, 1 mM 
MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 0.1% NP-40, 10% glycerol). Lysates were 
centrifuged at 4°C for 15 min at high speed. Cell lysate (500 μg) was incubated with 5 
μg poly(dI-dC) and 1 μg biotinylated SBE oligonucleotides containing Smad binding 
elements at 4°C for 16 h. DNA-bound proteins were collected with streptavidin beads 
(G-Biosciences, St. Louis, MO, USA) for 2 h. Beads were collected by centrifugation for 
30 s at 3000 g and washed four times with lysis buffer. Then, 2Xsample buffer (50 μL) 
was added to the beads and boiled for 5 min, followed by Western blotting. The SBE 
probe sequence for DNA pull-down was Biotine-5’- TCGATAGCCAG-
ACAGGTAGCCAGACAGGTAGCCAGACAGGTAGCCAGACAGG-3’ [193].  
 
3.3.13 Chromatin immunoprecipitation 
For the chromatin immunoprecipitation assay, a MAGnify chromatin 
immunoprecipitation system (Invitrogen) was used according to the manufacturer’s 
protocol. Briefly, cells were grown to 70~80% confluence in a 150-mm dish. The cells 
were crosslinked with 1% formaldehyde for 10 min at room temperature. Crosslinking 
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reactions were quenched with 0.125 M glycine for 5 min at room temperature. The cells 
were scraped and moved to a 1.5-mL tube, then sonicated for 8 cycles of 15 s on/1 min 
off. Sheared chromatin was incubated with either Smad2/3 antibody or normal IgG 
conjugated with beads for 2 h at 4°C. Chromatin-bound DNA was reverse cross-linked 
and DNA was purified. Purified DNA was subjected to qRT-PCR using the following 
primer pairs: TIMP3 promoter region, forward 5’- GCAAACAGCAGATGGCTTCC -3’ 
and reverse 5’- CCTTGACTGTGCTTGGTGGA - 3’; SMAD7 promoter region, forward 
5’- TTCTGGGAGCTTCTCTGCCC -3’ and reverse 5’- GCTCCGGCCTCGTCAC -3’.  
 
3.3.14 Interspecies heterokaryon assay 
The human U2OS cells grown in glass bottom dishes were transiently 
transfected with the pNAG-1/V5/His expression vector. At 24 h post transfection, the 
U2OS cells were washed with PBS twice, and then an equal number of murine NIH3T3 
cells were seeded onto the same glass bottom dishes. After 6 h incubation, 
cycloheximide (CHX, 100 μg/ml) and 10 nM LMB were added to inhibit protein synthesis 
and nuclear export of a protein. The co-cultured cells were washed twice with PBS after 
2 h and were added with polyethylene glycol MW 8000 (PEG) 50% (w/v) in PBS for 2 
min to allow cell fusion, followed by washing twice with serum-free medium containing 
CHX. The cells were then incubated with complete media (plus CHX along with LMB) 
for 1 h. After fixation in 4% paraformaldehyde, the cells were counterstained with 
Hoechst 33258 to distinguish human U2OS nuclei from those of murine NIH3T3 cells.  
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3.3.15 Statistical analysis 
Statistical analysis was performed with the Student unpaired t test. Results were 
considered statistically significance at *P < 0.05, **P < 0.01 and ***P < 0.001. 
 
3.4 Results 
 
3.4.1 Full-length wild-type NAG-1 (pro-NAG-1) translocates to the nucleus 
Because emerging evidence suggests that proteins exhibit distinctive activities 
based on cellular location, we decided to examine whether NAG-1 protein is located in 
different cellular regions. NAG-1 is first formed as pro-NAG-1 and then cleaved into a 
pro-peptide and a mature dimer form, which is then secreted into circulation. To 
investigate the cellular location of NAG-1 and the secretion events, we first used U2OS 
stable cell lines in which pro-NAG-1 is induced by treatment with tetracycline [191]. Only 
the pro-NAG-1 was present inside the cells with no mature form observed (Fig. 3.1A). 
Interestingly, nuclear/cytoplasmic fractionation of U2OS cells demonstrated that pro-
NAG-1 was equally expressed in both the cytoplasm and the nucleus in U2OS cells 
(Fig. 3.1B). Lamin A/C and tubulin α were used as controls for nuclear and cytoplasmic 
fractions, respectively. To confirm our finding, we constructed expression vectors for 
GFP- and V5/His-tagged NAG-1 and conducted an immunofluorescence assay to 
observe subcellular localization of NAG-1 in U2OS cells transiently transfected with the 
pNAG-1/GFP expression vector. NAG-1 signal (green) was observed in both the 
nucleus and the cytoplasm with a considerable signal in the ER/Golgi region (Fig. 3.1C). 
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NAG-1 seemed to be localized in nucleolus; however, NAG-1 expression was not 
confined to nucleolus, as shown in a co-localization experiment with fibrillarin, a marker 
for nucleolus expression (Supplementary Fig. S3.1A). To define the location of NAG-1 
in more detail, we performed subcellular fractionation, which separates cell components 
into soluble cytoplasmic extract (CE), membrane extract (ME), soluble nuclear extract 
(NE), and chromatin-bound protein extract (CB). As shown in Fig. 3.1D, pro-NAG-1 was 
expressed in both ME and NE fractions. Cell lysates from tet-inducible system and wild-
type U2OS cells transiently transfected with the pNAG-1/V5/His expression vector were 
separated into components. The phenomenon of finding pro-NAG-1 in nuclear fractions 
is observed both in the transient and stable NAG-1 expressing cells. Endogenous NAG-
1 expression is induced by treatment with several anti-cancer compounds in HCT-116 
human colorectal cancer cells [138]. As shown in Fig. 3.1E, HCT-116 cells incubated 
with anticancer compounds for 24 h express endogenous pro-NAG-1 in nucleus, 
suggesting a rapid translocation into the nucleus. A confocal microscopy analysis 
supports our finding that NAG-1 is present in the nucleus (Supplementary Fig. S3.1B). 
Overall, pro-NAG-1 is surprisingly expressed in the nucleus in addition to the membrane 
fractions, including the vesicle and ER/Golgi apparatus.  
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Figure 3.1 NAG-1 expression observed in the nuclear fraction.   
A, Western blot analysis of tetracycline-inducible U2OS cells. Cells grown in tet-free 
FBS were treated with 2 μg/mL tetracycline for the indicated times. Actin antibody 
was used for the loading control. B, Nuclear and cytoplasmic expression of NAG-1. 
Cytoplasm and nuclear fractions of inducible U2OS cells were isolated after 
stimulation with 2 μg/mL tetracycline for 24 h. Expression of NAG-1, lamin A/C 
(nuclear marker), and tubulin α (cytoplasmic marker) were analyzed by Western blot. 
C, U2OS cells transfected with GFP-tagged NAG-1 (WT) were fixed and analyzed by 
immunofluorescence with antibodies against GFP as described in the Materials and 
Methods section. DAPI was used to stain the nuclei. Two independent fields are 
shown. D, Tetracycline-induced U2OS (top panel) and wild-type U2OS cells 
transfected with NAG-1/V5/His expression vector (bottom panel) were subjected to 
subcellular fractionation, and Western blot was performed. CE, cytoplasmic extract; 
ME, membrane extract; NE, nuclear extract; CB, chromatin-bound extract. Markers in 
each fraction are shown. Sp3 exhibits multiple bands, and a 78 kDa band is shown. 
E, HCT-116 cells were treated with 10 μM of each compound for 24 h and subjected 
to Western blot analysis. MCC-555 is a PPAR ligand, whereas SS (sulindac sulfide) 
and TA (tolfenamic acid) are NSAIDs. DMSO was used for a vehicle.  
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Figure 3.1 Continued.  
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3.4.2 NAG-1 may contain a non-canonical nuclear localization signal 
domain and is imported to the nucleus via the nuclear pore complex.  
Since NAG-1 does not contain the classical nuclear localization signal (NLS), two 
independent programs were used to search for the non-classical NLS [194, 195]. Both 
programs found one potential non-classical NLS (aa 190-197). Another potential NLS 
(aa 211-218) was selected by only one program. Subsequently, two deletion mutant 
clones (Δ190-197 and Δ211-218) from the NAG-1/V5/His expression vector were 
generated (Fig. 3.2A) and expressed in wild-type U2OS and HCT-116 cells. 
Nuclear/cytoplasmic localization showed that the expression level of the two NAG-1 
mutants was higher in the cytoplasmic fraction than in the nucleus, in both cell types 
(Fig. 3.2A). These data are further confirmed by subcellular fractionation, indicating that 
Δ190-197 NAG-1 has less NAG-1 expression in the nuclear extraction (Supplementary 
Fig. S3.2A). Thus, these mutant NAG-1 proteins are still translocated into the nucleus 
but at a much lower amount, compared to wild-type NAG-1. These results were 
confirmed by immunofluorescence analysis with NAG-1/GFP construct, indicating that 
less signal intensity of mutant NAG-1-transfected cells was observed in the nucleus, 
compared to wild-type NAG-1-transfected cells (Fig. 3.2B). Thus, these two regions, aa 
190-197 and aa 211-218, may contribute, at least in part, to translocation of NAG-1 
protein from the cytoplasm to the nucleus. It has been reported that a protein can have 
multiple NLS that may function cooperatively to affect efficient nuclear transport [196, 
197]. Since two putative NLS sites exhibit a marginal effect on nuclear entry of NAG-1, 
serial deletion mutant clones were generated to address this issue. As shown in Fig. 
3.2C, none of the clones resulted in a higher ratio of cytoplasmic NAG-1 to nuclear 
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NAG-1. However, the expression of one NAG-1 mutant clone (Δ2-29 clone) resulted in 
predominant expression in the nucleus (Fig. 3.2C). To determine whether this 
translocation requires energy and/or the nuclear pore complex, an in vitro nuclear 
import assay was performed using NAG-1/GFP fusion proteins. Permeabilized cells lose 
their transport systems; therefore, cytosolic extract and the ATP/GTP regenerating 
system were provided to investigate nuclear uptake of NAG-1/GFP. As shown in Fig. 
3.2D, NAG-1/GFP protein localized in the nucleus, whereas GFP protein alone did not. 
These results suggest that NAG-1/GFP does not enter the nucleus by a simple diffusion 
pathway because of the large size of the NAG-1/GFP protein (more than 60 kDa), and 
that ATP is required to transport NAG-1 into the nucleus. In addition, inactivation of the 
nuclear pore complex (NPC) by wheat germ agglutinin (WGA) abolished NAG-1 
movement to the nucleus. Since the secreted NAG-1 cannot be absorbed by the cells 
(Supplementary Fig. S3.2B), only cytoplasmic NAG-1 is subjected to nuclear entry. 
Taken together, these results indicate that the nuclear entry of NAG-1 is energy-
dependent via the nuclear pore complex, and those two sites (190-197 and 211-218), in 
part, contribute to the nuclear entry of NAG-1.  
 
3.4.3 NAG-1 has a canonical nuclear export signal (NES) mediated by CRM1 
Next, we decided to further analyze the 2-29 region of NAG-1, as shown in Fig. 
3.2C, in terms of nuclear accumulation of NAG-1. We generated more deletion clones 
within this region and found that the Δ14-29 clone contains a domain to control  
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Figure 3.2 NAG-1 moves to the nucleus through a nuclear pore complex in an 
energy-dependent manner.  
A, Schematic diagrams of plasmids encoding different truncated forms of NAG-1, Δ190-
197, and Δ211-218. Deletion sequences are presented in the bottom panel. Pro-NAG-1 
(Wild-type) is designated at the top: propeptide (yellow), mature peptide (blue), followed 
by V5 epitope and histidine track (red). C, cytoplasmic and N, nuclear fractions of U2OS 
(bottom left panel) and HCT-116 (bottom right panel) cells transfected with either WT or 
two mutant clones were subjected to Western blot. Antibodies against lamin A/C and 
Tubulin α were used for nuclear and cytoplasm markers, respectively. Intensity ratio for 
cytoplasmic to nuclear (C/N) expression is shown at the bottom. B, 
Immunofluorescence assay with antibodies against V5 from WT and two mutant NAG-1-
transfected U2OS cells. DAPI was used for staining nuclei. Representative fields are 
shown. C, Schematic diagram of serial deletion mutants of NAG-1. HCT-116 cells were 
transfected with each mutant clone as described in the Materials and Methods section, 
and Western blot analysis was performed using C and N fractions. Intensity ratio for C/N 
expression is shown at the bottom. D, In vitro nuclear import assays of NAG-1/GFP 
protein. HCT116 cells were permeabilized with digitonin (30 ng/ml) for 5 min and then 
incubated in a reaction buffer containing cytosol extract and ATP regeneration system 
with either NAG-1/GFP or GFP protein. For WGA treatment, permeabilized cells were 
pre-incubated with 0.05 mg/mL WGA for 30 min at room temperature and incubated for 
30 min at 37°C with complete reaction buffer. The cells were washed with reaction 
buffer and then fixed and stained with DAPI. The cells were viewed by fluorescence 
microscopy. Right panel, expression of in vitro translated GFP and NAG-1/GFP by 
Western blot. 
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Figure 3.2 Continued. 
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predominantly nuclear expression of NAG-1 (Supplementary Fig S3.3A, B). We also 
generated a glycosylation site mutant clone (N70A) because it has been known that 
glycosylation sites may affect nuclear translocation of proteins [198]. This clone showed 
an expression pattern of NAG-1 similar to that of wild-type (Supplementary Fig. S3.3A). 
As shown in Fig 3.3A, the Δ14-29 clone exhibited higher expression of NAG-1 in the 
nucleus (lane 3 vs 7). As a control, we transfected an R193A mutant clone that cannot 
be cleaved at the RXXR site and wherein mature NAG-1 cannot form. To elucidate if the 
Δ14-29 mutant clone altered secretion of the mature form, conditioned medium from the 
same batch used in Fig. 3.3A was purified, and secreted mature NAG-1 was measured 
by Western blot analysis. As expected, both pro-NAG-1 and mature NAG-1 (Fig. 3.3B, 
lane 2) were detected in pNAG-1/V5 transfected medium, while the R193A clone 
secreted only the pro-NAG-1 (Fig. 3.3B, lane 4). However, we could not detect Δ14-29 
pro-NAG-1 nor mature NAG-1 in the culture medum (Fig. 3.3B, lane 3). These data 
indicate that the Δ14-29 region is necessary for exporting pro-NAG-1 protein to the 
cytoplasm from the nucleus and thus no mature NAG-1 is present in the media.  
Our results also indicate a putative NES sequence in the Δ14-29 region [199]. 
Therefore, two mutants (ΔNES and mutNES) were generated to investigate whether the 
Δ14-29 region plays a role in nuclear exportation of NAG-1 (Fig. 3.3C). The expression 
pattern of NAG-1 in U2OS cells with a ΔNES or mutNES construct showed essentially 
nucleus expression with little to no cytoplasm expression in contrast with the wild-type 
NAG-1 control (Fig. 3.3C and Supplementary Fig. S3.4A). Confirmation of nuclear 
expression was obtained with immunofluorescence of U2OS cells transfected with 
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pNAG/ΔNES/V5 and pNAG/mutNES/V5 constructs (Fig. 3.3D). Chromosome region 
maintenance 1 (CRM1; also referred to as exportin1 or Xpo1) is a key protein in 
exporting a protein from the nucleus into the cytoplasm [200]. To determine whether 
CRM1 is involved in NAG-1 exportation, we added the CRM1 inhibitor leptomycin B 
(LMB) to the cells to see nuclear retention of NAG-1. The pro-NAG-1 nuclear 
distribution was increased in the cells treated with LMB in a dose-dependent manner 
(Supplementary Fig. S3.4B, C and D). Smad4 was used as a control because it is 
regulated by CRM1 in exportation out of the nucleus [201]. Finally, we conducted an 
immunoprecipitation assay to determine whether pro-NAG-1 physically interacts with 
CRM1. As shown in Fig. 3.3E, pro-NAG-1 was indeed immunoprecipitated with CRM1, 
suggesting that NAG-1 exportation to the cytoplasm is controlled by CRM1. There is a 
possibility that the 14-29 aa region of NAG-1 may have signal sequences for direct 
secretion to the extracellular region in addition to those for exportation from the nucleus. 
To address this possibility, we observed the level of NAG-1 secretion after LBM 
treatment. As expected, LMB treatment blocked NAG-1 secretion, suggesting that the 
14-29 aa region is not only for exportation from the nucleus but also for secretion (Fig. 
3.3F). To further support the evidence that an NES exists in NAG-1, we employed the 
interspecies heterokaryon assay (Supplementary Fig. S3.4E), the results of which 
suggested that NAG-1 shuttles between the nucleus and the cytoplasm, and LMB 
treatment blocks nucleocytoplasmic shuttling properties of NAG-1.   
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Figure 3.3 A canonical nuclear export signal (NES) of NAG-1 contributes 
predominant nuclear expression of NAG-1.   
A, HEK293 (left panel) and HCT-116 (right panel) cells were transfected with either 
control LacZ vector, full-length pNAG-1-V5-WT (FL), or the two mutant clones pNAG-1-
V5 Δ14-29 and pNAG-1-V5 R193A. Then the cytoplasm and nuclear fractions were 
isolated. Western blot analysis was performed against V5, tubulin α, and lamin A/C. B, 
Conditioned media from (A) were harvested and concentrated by Corning 
concentrations (10 kDa MWCO), and 30 μL concentrated conditioned media was 
analyzed by Western blot with anti-V5 antibody. C, A putative NES in the N-terminal 
domain of NAG-1. The putative NES sequence in human NAG-1 is aligned with NAG-1 
in other species, and also compared with the known NES sequences in Smad4, Hsc70, 
and PKI. Two mutant NAG-1 clones, ΔNES and mutNES, are shown. U2OS cells were 
transfected with the indicated vectors. Nuclear, N, and cytoplasmic, C, fractions were 
analyzed using the indicated antibodies as shown at bottom. D, U2OS cells were 
transfected with WT, ΔNES, or mutNES NAG-1-expressing vectors, and 
immunofluorescence assay was performed with antibodies against V5 (green) with 
DAPI staining (blue). Scale bars, 10 μm. E, Tet-inducible U2OS cells were treated with 
2 μg/mL tetracycline for 24 h, and cell lysates were isolated with a modified RIPA buffer 
as described in the Materials and Methods section. The cell lysates were incubated 
overnight with 2 μg CRM1 or normal IgG antibodies, subjected to immunoprecipitation 
for 3 h, and then subjected to Western blot analysis using NAG-1 or CRM1 antibodies. 
The whole cell lysate (WCL) was loaded with 30 μg. F, U2OS cells were transfected 
with pNAG-1/V5/His WT for 6 h, then 10 nM LMB added for 18 h. Conditioned media 
from the cells was subjected to Western blot analysis. 
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3.4.4 RNA-seq analysis suggests that NAG-1 inhibits the expression of 
TGF-β target genes 
To date, little is known about the NAG-1 receptor and its downstream pathways. 
Transcriptome sequencing (RNA-seq) is a promising tool in elucidating downstream 
effects and/or pathways. To study the effects and downstream pathways of NAG-1, we 
employed comparative RNA-seq profiling of the transcriptomes using U2OS and tet-
induced U2OS cells. RNA-seq results revealed 142 differentially expressed genes (Fig. 
3.4A). Nineteen of the 142 genes were previously reported to be a potential TGF-β 
target gene with regard to their relative abundance presented in the heat map (Fig. 
3.4B). Ingenuity network analysis was used to identify possible interactions with other 
genes differentially expressed in our dataset, and suggested NAG-1 expression 
reduced the expression of several TGF-β1-related genes (Fig. 3.4C). Although we did 
not treat the cells with TGF-β1 for RNA-seq experiments, U2OS cell lines 
spontaneously secrete TGF-β1 in an autocrine loop for homeostasis (Supplementary 
Fig. S3.5). We selected 10 out of 19 genes because they are well-known Smad target 
genes and confirmed their expression in the cells transfected with pNAG-1/His/V5 
expression vector by qRT-PCR (Fig. 3.4D). Except for HMGA1, the expression of NAG-
1 inhibited the expression of these downstream targets of TGF-β1, suggesting pro-
NAG-1 acts as an inhibitor of the TGF-β1 pathway. To examine further the effect of 
NAG-1 on the TGF-β signaling pathway, two promoter reporters, p3TP-Luc and pPAI-
800-Luc, were transfected into two TGF-β-responsible U2OS and HEK293 cells with 
NAG-1 expression vector. NAG-1 expression diminished TGF-β1-mediated Smad  
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Figure 3.4 NAG-1 modulates TGF-β signaling at the transcriptional level.   
A, The scatter plot from RNA-seq data compares the expression of inducible U2OS 
cells with or without tetracycline. The straight line highlights the general similarities 
between the two conditions, with the volcano plot (red for up-regulation, green for down-
regulation) showing the differentially expressed genes (Supplementary Table 2). B, 
Heat map representation of the mRNA expression profile showing changes in TGF-β 
downstream target genes between U2OS and tetracycline-treated U2OS cells. Gene 
expression data were log2 transformed and then normalized prior to generating the heat 
map for direct comparison of data. Differential expression for each cell is presented. C, 
Schematic representation of Ingenuity network analysis. Gene symbols are in red and 
green for up- and down-regulation, respectively. Dashed lines show indirect 
interactions, while continuous lines represent direct interactions, based on Ingenuity’s 
knowledgebase. D, Real-time PCR of selected genes from the heat map. Empty vector 
(EV) or wild-type (WT) NAG-1 was transfected into U2OS cells and total RNAs isolated; 
then qRT-PCR was performed as described in the Materials and Methods section. The 
data were normalized by the expression of the housekeeping Ribosomal Protein, Large, 
P0 (RPLP0) mRNA, and further normalized to the level of the empty vector transfected 
group, which was set at 1. E, Two reporter genes, p3TP-Luc and pPAI-800-Luc 
(SERPINE1 promoter), were co-transfected with either empty vector or NAG-1-
expressing vector into U2OS and HEK293 cells that exhibited an intact TGF-β signaling 
pathway. Transfected cells were treated with TGF-β1 (10 ng/mL for 24 h), and 
luciferase activity was measured. The graph shows mean values with ± SD from three 
replicates. *P < 0.05, compared to TGF-β1-treated empty vector-transfected cells.
 77 
 
 
Figure 3.4 Continued. 
 78 
 
activities (p3TP-Luc and pPAI-800-Luc) (Fig. 3.4E). Thus, pro-NAG-1 expression 
inhibits the TGF-β1-mediated Smad signaling pathway at the transcriptional level.  
 
3.4.5 Nuclear NAG-1 mitigates TGF-β signaling via interrupting Smads to 
DNA binding   
To address to what extent NAG-1 is relevant to endogenous Smad target genes, 
we treated the cells with TGF-β1 and measured the expression of the known TGF-β 
target genes SERPINE1, TIMP3, and LTBP1. Gene expression was suppressed in the 
presence of NAG-1 and further suppressed in the presence of ΔNES-NAG-1, which is in 
agreement with a higher level of nuclear pro-NAG-1 (Fig. 3.5A). In U2OS and MCF10A 
cells (TGF-β1-responding cells), wild-type NAG-1 and mutNES NAG-1 expression 
inhibited the Smad pathway, as assessed by Smad binding element (SBE) reporter 
activity (Fig. 3.5B). Similar results were observed in MCF7 cells using p3TP and PAI-1 
reporters (Supplementary Fig. S3.6A). Expression of the R193A mutant, which does not 
produce the mature NAG-1, also inhibited TGF-β-mediated Smad transcriptional activity 
(Supplementary Fig. S3.6B), supporting the hypothesis that pro-NAG-1, but not mature 
NAG-1, is involved in the inhibition of Smad signaling.  
To further investigate how NAG-1 modulates the TGF-β1 response, we 
measured the level of phosphorylation of Smad2 in the presence of TGF-β1. Wild-type 
U2OS cells were transfected with either empty or NAG-1 expression vector and then 
treated with TGF-β1 for 1 h. Next, the treatment medium was aspirated and fresh  
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Figure 3.5 Nuclear NAG-1 interrupts DNA binding activity of the Smad complex.   
A, Real-time PCR for expression of SERPINE1, TIMP3, and LTBP1 genes in the 
presence of TGF-β1. U2OS cells were transfected with empty (EV), wild-type NAG-1 
(WT), or ΔNES NAG-1-expression vectors. Cells were treated with TGF-β1 (2 ng/mL) 
for 12 h, and gene expression was analyzed by qRT-PCR as described in the Materials 
and Methods section. The graph shows mean values of fold changes over TGF-β1 
treatment. B, Wild-type NAG-1 and mutNES-NAG-1 expression decreased Smad 
binding element (SBE)-containing promoter activity.  MCF-10A and U2OS cells were 
transfected with SBE4 reporter and indicated expression vectors. Cells were treated 
with TGF-β1 (10 ng/mL) for 24 h and luciferase activity measured. The graph shows 
mean values ± SD from three replicates. ***P < 0.001, compared to TGF-β1-treated 
empty vector-transfected cells. C, U2OS cells were transfected with either empty or 
wild-type NAG-1 expression vector. After treatment with TGF-β1 (2 ng/mL) for 1 h, the 
media were replaced with fresh media, and cell lysates were isolated at the indicated 
time points. Whole cell lysates (30 μg) were subjected to Western blot analysis using 
p21, phosphor-Smad2, and Smad2 antibodies. D, Tet-inducible U2OS cells were 
stimulated with TGF-β1 (2 ng/mL) for the indicated time points, and then cell lysates 
were subjected to nuclear and cytoplasmic fractionation followed by Western blot with 
the indicated antibodies. Lamin A/C and tubulin α were used as nucleus and cytoplasm 
markers, respectively. E, DNA pull-down and Western blot with anti-Smad2/3 and anti-
Smad4 antibodies. Cell lysates from either U2OS or U2OS-tet cells were incubated with 
SBE oligo DNA as described in the Materials and Methods section. SBE-bound proteins 
were reduced in U2OS-tet compared to U2OS (left panel), and similar results were 
obtained using ectopic NAG-1 expression vectors into U2OS cells (right panel). F, In 
vivo binding of Smad2/3 to the TIMP3 or Smad7 promoter in U2OS cells stimulated with 
TGF-β1 (2 ng/mL) using the ChIP assay. Inducible U2OS cells were stimulated by 
tetracycline for 24 h (left panel), and wild-type U2OS cells were transfected with either 
empty vector or NAG-1 expressing vector (right panel). The ChIP assay for endogenous 
smad2/3 indicates enhanced recruitment of Smad2/3 to the TIMP3 or Smad7 promoter 
region after simulation with TGF-β1 for 3 h and decreased occupancy on these 
promoter regions by NAG-1 expression
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Figure 3.5 Continued. 
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medium added. The cells were finally harvested in a time course for Western blot 
analysis. Pro-NAG-1 modulated p21 expression (a TGF-β target gene) in response to 
TGF-β1 without affecting phosphor-Smad2 signal duration (Fig. 3.5C), suggesting that 
upon TGF-β1 stimulation, NAG-1 inhibits TGF-β1 signaling without inhibiting 
phosphorylation of Smad2. To examine if pro-NAG-1 affects the translocation of Smad2 
to the nucleus and Smad2 degradation, the distribution of Smad2 was investigated. As 
shown in Figure 5d, Smad2 distribution was the same in both cytosol (lanes 1, 2 vs 3, 4) 
and the nucleus (lanes 6, 7 vs 8, 9), regardless of whether NAG-1 was present. 
Furthermore, this result was confirmed using A549 cells that were transfected with 
either LacZ or ΔNES NAG-1, and the distribution of Smad2 between cytosol and 
nucleus was examined (Supplementary Fig. S3.6C). Thus, pro-NAG-1 did not affect 
Smad2 translocation into the nucleus upon TGF-β1 stimulation or Smad2 degradation. 
We next explored whether the DNA-binding activity of Smad was diminished by NAG-1 
expression. The DNA pull-down assay indicated that SBE binding activity of the Smad 
complex was diminished when NAG-1 was expressed, implying that NAG-1 may 
interrupt Smad DNA-binding activity in the nuclear region (Fig. 3.5E, Supplementary 
Fig. S3.6D). Furthermore, a ChIP assay showed that NAG-1 inhibits binding of Smad to 
the promoter region of TGF-β target genes (Fig. 3.5F). Taken together, these results 
suggest that nuclear pro-NAG-1 attenuates TGF-β-mediated Smad signaling through 
interruption of DNA binding activity of the Smad complex upon TGF-β1 stimulation.  
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3.4.6 NAG-1 Attenuates TGF-β-induced cell migration 
TGF-β1 is a cytokine that increases cell migration and invasion[202]. We next 
examined if NAG-1 expression altered TGF-β1-induced cell migration. As shown in Fig. 
3.6A, NAG-1 expression diminished cell migration into the scratched region in response 
to TGF-β1. In addition, a trans-well migration assay showed less migration in the NAG-
1- or mutNES-NAG-1-expressing cells in comparison to the empty vector-transfected 
cells (Fig. 3.6B). We employed a 3D culture system to study invasion. Spheroids 
composed of empty vector-transfected cells exhibited spindle-like protrusions after TGF-
β1 treatment; however, spheroids composed of WT-expressing or mutNES-expressing 
cells did not (Fig. 3.6C). NAG-1 also suppressed expression of snail1 and slug, which 
are markers for epithelial–mesenchymal transition (EMT) induced by TGF-β1 
(Supplementary Fig. S3.7). Overall, NAG-1 expression appeared to suppress EMT and 
cell invasion activity of TGF-β1 by inhibiting Smad DNA-binding activity.  
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Figure 3.6 NAG-1 blocks TGF-β1-induced cell migration/invasion. 
A, Cell migration assay. Tet-inducible U2OS cells were scratched with a pipet tip, 
and images were taken at 0 and 24 h by phase-contrast microscopy as the cells 
repopulated the wound. To measure the rate of healing, the area between the wound 
edges was measured and compared relative to the area of the original wound at t = 
0. Dotted lines represent the original wound area.  The graph (right panel) shows 
mean values with ± SD from three replicates (*P < 0.05). B, Transwell migration 
assay. Transwell chambers were used to verify migration potential. U2OS cells 
transfected with the indicated vector were incubated with 10 ng/mL TGF-β1 for 18 h. 
Cells attached in the lower section were stained with crystal violet and counted under 
a light microscope. The graph shows mean ± SD of three independent experiments 
(*P < 0.05 and **P <0.01). C, U2OS cells transfected with either empty, wild-type 
NAG-1, or mutNES NAG-1 were prepared and subjected to an in vitro 3-D spheroid 
cell invasion assay as described in the Materials and Methods section. The green 
arrow indicates cells invading the surrounding invasion matrix 
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3.5 Discussion 
Multiple cellular localizations of protein give rise to multiple functions or integrate 
signals from different locations to fulfill one biological outcome [41, 75, 190, 203]. NAG-
1 is a secreted TGF-β superfamily member, and plays a role as a cytokine to affect 
several biological activities through an unknown receptor. While working on cellular 
NAG-1 movement, we discovered that NAG-1 is significantly expressed in the nucleus 
and affects transcriptional regulation of the Smad complex. NAG-1 expression is altered 
by a variety of signals, such as those from cytokines (IL-1β, TNF-α, macrophage 
colony-stimulating factor) [172], radiation [171], tissue injury [204], anoxia [205], and 
many chemopreventive/chemotherapeutic chemicals [206], suggesting NAG-1 signaling 
may be important for maintaining cellular homeostasis. In addition, NAG-1 is a target 
gene of several transcription factors, such as p53 [171, 207], NF-κB [208], Sp1 [141], 
and Egr-1 [120]. However, downstream signaling pathways affected by NAG-1 remain 
to be discovered.  
Although in vitro assays show different results, the results from NAG-1 over-
expression in NAG-Tg mice and NAG-1 depletion in NAG-1 knockout mice consistently 
support the notion for anti-tumorigenic activity [167, 168, 209]. Some possible 
explanations for the contradictory activity of NAG-1 in vitro include: 1) NAG-1’s different 
functions in the different cancer types, 2) an unidentified role of pro-NAG-1 in cells, and 
3) the contribution of NAG-1 binding proteins or receptors in different cells. In fact, there 
are many examples of other proteins having dual biological functions in different cancer 
types and microenvironments. For example, EGR-1 has been shown to be associated 
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with pro-tumorigenic activity in prostate cancer [210], whereas EGR-1 acts like a tumor 
suppressor protein in other cancers [211]. 15-lipooxygenase-1 (LOX-1) is another 
example; LOX-1 acts as a tumor suppressor in colorectal cancer and a pro-tumorigenic 
protein in prostate cancer [212, 213]. Thus, the fact that NAG-1 shows dual functions in 
carcinogenesis is not surprising. Lack of knowledge of NAG-1's receptor and/or binding 
proteins is a large hurdle to studying its signaling pathway; however, a couple of reports 
have suggested that NAG-1 may be involved in TGF-β receptor-mediated signaling 
[171, 214]. Based on our data, we were surprised to find that NAG-1 expressed in the 
nucleus, and that nuclear NAG-1 inhibited the TGF-β1-induced Smad complex, thereby 
inhibiting expression of Smad target genes. This observation consistently occurred in 
different cell lines. Therefore, our data suggest that inhibition of the Smad pathway by 
nuclear NAG-1 expression may provide a new avenue to support NAG-1’s role in anti-
tumorigenesis.   
Our results suggest that NAG-1 could translocate into the nucleus through an 
active transport system (Fig. 3.2D); however, we have yet to define the precise 
mechanisms involved in its nuclear importation. It is likely that multiple pathways or a 
novel pathway may affect NAG-1 movement to the nucleus since two potential 
mutations partially affected NAG-1 importation, and no canonical NLS signals were 
found in the NAG-1 full-length peptide sequences (Fig. 3.2A and B). The TGF-β 
superfamily member BMP2 has been observed in a truncated form in the nucleus [215]; 
however, the current study is the first report that a full-length TGF-β superfamily protein 
expresses in the nucleus and plays a role in transcription. Nuclear importation of NAG-1 
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requires energy and carrier proteins. GFP by itself was not able to enter nuclei (Fig. 
3.2D); however, NAG-1/GFP was imported into the nucleus as examined by an in vitro 
import assay. Depleting the energy generation system and NPC inhibitor WGA 
treatment in the permeabilized cells reduced nuclear uptake of NAG-1, suggesting that 
NAG-1 nuclear entry occurs through the NPC in an energy-dependent manner. Given 
that NAG-1 lacks a classical NLS region and requires the NPC for translocation, nuclear 
localization of NAG-1 likely requires interaction with a partner that contains the NLS 
domain [216]. Indeed, nuclear importation of protein can be mediated by multiple 
transport receptors [196, 197], or a protein can directly interact with a component of 
nuclear pore proteins containing armadillo repeats [217]. Thus, it is likely that a portion 
of NAG-1 is exposed to the cytoplasm while another portion of NAG-1 is embedded in 
ER/Golgi for being recognized by a transporter, as seen in EGFR nuclear importation 
[218]. Although we have not ruled out these possibilities, our data indicate that two sites 
(190-197 and 211-218) play a role, at least in part, in importing NAG-1 to the nucleus. 
Further experiments are necessary to define the molecular mechanism of nuclear 
transport and specifically, the exact component of import machinery for NAG-1.  
In comparison to the importation mechanism of NAG-1, we were able to 
investigate in greater detail NAG-1 exportation to the cytoplasm. NAG-1 export was 
mediated by a LMB-sensitive, CRM1-dependent pathway, which requires a functional 
domain to be recognized by CRM1. Sequence analysis showed that the canonical, 
leucine-rich NES was present within the N-terminal region of NAG-1. If this site were 
deleted or mutated, then NAG-1 was retained in the nucleus of the cells. We also 
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observed that NAG-1 physically bound to CRM1; however, we cannot exclude the 
possibility that other nuclear proteins that supply NES may help NAG-1 exportation. 
Interestingly, we could not find secreted mature NAG-1 in the culture media when NAG-
1 was retained in the nucleus. It is likely that one of the secretion pathways of NAG-1 
must pass through the nucleus prior to processing to the mature form. Vesicles are 
required for NAG-1 secretion, and the vesicle containing NAG-1 may form at the nuclear 
membrane; therefore, an NES sequence may play a pivotal role in vesicle formation. 
Indeed, our results show that NAG-1 is localized in the ER/Golgi region in the 
cytoplasm, not as a soluble cytosolic fraction (Fig. 3.1D) and that this localization is 
dependent upon sequences in the N-terminal domain, a region that contains an NES 
sequence (Fig. 3.3C). Notably, there is a possibility that anti-tumorigenic activity of 
NAG-1 may occur with nuclear NAG-1, whereas secreted mature NAG-1 protein may 
possess pro-tumorigenic activity. This is supported by previous reports indicating that 
recombinant NAG-1 increases kinase pathways in some cancer cells [219]. Although 
further mechanistic studies are required to define the exact biological activity of nuclear 
NAG-1 and secreted mature NAG-1, our data clearly show that nuclear NAG-1 causes 
inhibition of cell migration and invasion, as assessed by experiments with mutants.  
The biological role of NAG-1 nuclear-cytoplasmic shuttling remains to be 
established. In this study, we found that nuclear NAG-1 could control the strength of 
TGF-β1-mediated Smad signaling. It remains to be clarified how nuclear NAG-1 
modulates the DNA binding capacity of the Smad complex, even though it has been 
known that various factors and cellular context attenuate Smad-mediated transcription. 
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One possible way is that NAG-1 might bind directly to DNA (SBE) to compete with 
Smad, although no DNA binding motif has been identified in the NAG-1 sequence. To 
test this hypothesis, we employed ChIP-seq to see if any DNA fragments were pulled 
down with NAG-1. It is not likely that NAG-1 directly binds to conserved SBE, since we 
have not identified any genes related to the SBE-containing promoter. Another 
possibility is that NAG-1 may bind to phosphor-Smad2, thereby inhibiting Smad binding 
activity. However, we could not find any direct physical interaction between Samd2/3/4 
and NAG-1 (Supplementary Fig. S3.8). Our data rather imply that NAG-1 somehow 
interrupts the Smad complex in the nucleus by unknown mechanism(s). Smad proteins 
may need an additional transcription factor or co-factor to strongly occupy their target 
DNA [43, 220]. Thus, NAG-1 might disrupt the formation of the Smad complex upon 
TGF-β1 stimulation, or NAG-1 might somehow facilitate ADP-ribosylation, which 
dissociates the Smad complex from DNA, leading to attenuation of a Smad-specific 
gene response [221].  
Our data show that all the cells tested tended to express NAG-1 in varying amounts 
in both the cytoplasm and nucleus (Fig. 3.3A). This provides a model that could 
demonstrate strategies for therapeutic intervention in disease states in which 
“inappropriate” localization of protein is believed to contribute to disease development 
[222, 223]. It remains to be elucidated whether more transformed tumor cells activate 
mechanisms that allow increased nuclear import or decreased nuclear export of NAG-1. 
We are currently developing an antibody that recognizes the N-terminal region of NAG-
1 to examine NAG-1 expression in the nucleus of human tissue samples and to 
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determine whether more nuclear staining of NAG-1 is associated with a better prognosis 
in cancer patients.  
 
3.6 Summary Conclusion 
In summary, our data indicate that the pro-NAG-1 was expressed in the nucleus 
and appears to play a role in transcriptional regulation by disturbing the Smad complex. 
In addition, nuclear retention resulted in an absence of secreted mature NAG-1. The 
schematic diagram in Fig. 3.7 represents the proposed model of the molecular 
mechanism of nuclear-cytoplasmic NAG-1 shuttling through active transport and nuclear 
NAG-1 attenuating TGF-β signaling through interruption of DNA binding of the Smad 
complex upon TGF-β stimulation. In addition, the novel role of NAG-1 in the nucleus 
may help lead to the development of new drugs that facilitate the retention of NAG-1 in 
the nucleus or to the development of novel diagnostic tools for assessing cancer 
progression.  
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Figure 3.7 A proposed model for nuclear-cytoplasmic shutting and the 
function of NAG-1 in the nucleus.  
Cytoplasmic NAG-1 is recognized by import machinery and enters the nucleus 
via the NPC in an energy-dependent manner. In the nucleus, NAG-1 interrupts 
the DNA binding capacity of the Smad complex giving rise to attenuation of Smad 
signaling. Nuclear NAG-1 interacts with CRM1 for export out of the nucleus. 
NAG-1 is secreted by an unknown secretory pathway and likely binds to an 
unidentified receptor. 
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CONCLUSION 
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The studies presented in this dissertation contribute to the better understanding 
of regulatory mechanism that control NAG-1 expression in response to PPARγ-ligand 
and identify nuclear NAG-1 that may decipher the molecular basis of NAG-1’s dual 
effects in cancer. Our findings will pave the way for the new avenue in future studies 
which attempt to understand how NAG-1 coordinates with the intracellular signaling 
component(s) such as KLF4 and PPARγ to modulate a proper cellular response at a 
given cellular context and how nuclear NAG-1 participates in regulating gene 
expression which is either negative or positive in tumor cell growth and survival based 
on cellular context. This work will shed light on the relationship between nuclear NAG-1 
and tumorigenesis that could suggest NAG-1 may be served as a potential biomarker/or 
a therapeutic target for the diagnosis and treatment during cancer progression  
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Supplementary Figure S2.1 KLF4 RNA is increased in the presence of MCC-
555, KLF4 induction by MCC-555 appears to not involve PPARγ activation. 
A, BxPC-3 cells were pretreated with GW9662 for 30 min at the indicated dose and 
then the cells were treated with 10 μM of MCC-555 for 24 h. Total proteins were 
isolated for Western blot analysis. Equal loading was confirmed by Actin. B, Total 
RNAs were isolated from BxPC-3 cells after MCC-555 treatment. The expression of 
transcripts for KLF4 was analyzed by RT-PCR. GAPDH was used as control 
transcript. 
 
 109 
 
 
 
 
Supplementary Figure S3.1 Nuclear localization of NAG-1.  
A, Immunofluorescence for fibrillarin. U2OS cells transfected with GFP-tagged 
NAG-1 (WT) were fixed and analyzed by immunofluorescence with antibodies 
against GFP and fibrillarin, as described in the Materials and Methods section. 
DAPI was used to stain the nuclei. Two independent fields are shown. B, 
Confocal microscope image of subcellular localization of NAG-1. HCT-116 
cells were transfected with pNAG1-GFP expression vector, and the cells were 
counterstained with propium iodide. A representative picture is shown. A 
confocal microscope (Leica, TCS SP2) was used and Leica software (version 
2.61) was used to collect the images.  
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Supplementary Figure S3.2 Cytoplasmic NAG-1 is subjected to nuclear 
translocation. 
A, Wildtype U2OS cells transfected with either pNAG-1/V5/His WT expression 
vector or pNAG-1/V5/His Δ190-197 were subjected to subcellular fractionation, 
and Western blot was performed. CE, cytoplasmic extract; ME, membrane 
extract; NE, nuclear extract; CB, chromatin-bound extract. Markers in each 
fraction are shown. B, U2OS cells were treated with the conditioned media of 
HCT-116 cells from Fig. 3.3B for 24 h, and cell lysates were isolated in RIPA 
buffer followed by Western blot analysis. Cell lysate pNAG-1/V5/His WT 
transfected cells were loaded as a control (lane 3). 
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Supplementary Figure S3.3 NAG-1 has a nuclear retention signal within aa 14-
29.  
A, HEK293 cells were transfected with GFP, NAG-1/GFP expression vector, or the 
mutant constructs that are conjugated with GFP. Both cytoplasm and nuclear 
fractions were isolated, and Western blot analysis was performed against GFP, 
tubulin α, and lamin A/C. B, HEK293 cells were transfected with LacZ expression 
vector or indicated NAG-1 expression vectors conjugated with V5. Both cytoplasm 
and nuclear fractions were isolated, and Western blot analysis was performed 
against V5, tubulin α, and lamin A/C. 
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Supplementary Figure S3.4 NAG-1 possesses a nuclear export signal (NES). 
A, U2OS and HCT-116 cells were transfected with mutNES clone, and subcellular 
fraction was isolated. Western blot analysis was performed using antibodies against 
V5, Hsp90, calnexin, Sp3, or histone H1. CE, cytoplasmic extract; ME, membrane 
extract; NE, nuclear extract; CB, chromatin bound extract. B, Tet-inducible U2OS 
cells were treated with 2 μg/mL tetracycline for 16 h, and cells were treated with 
CRM1 inhibitor LMB for 5 h with various doses. Cytoplasmic fraction was isolated, 
and Western blot was performed using antibodies against NAG-1 and tubulin α. C, 
HEK293 cells were transfected with pNAG-1/V5/His WT expression vector, and the 
cells were treated with LMB for 5 h at various doses. The nuclear fraction was 
isolated, and Western blot was performed using antibodies against V5, Smad4, and 
lamin A/C. D, HEK293 cells transfected with NAG-1/V5 expression vector with or 
without 10 nM LMB treatment for 5 h were subjected to immunofluorescence assay. 
NAG-1/V5 was detected by FITC conjugated secondary antibody (green), and the 
nuclei were stained with DAPI (blue). E, Effect of LMB on shuttling of NAG-1. 
Interspecies heterokaryons were prepared and viewed as described in the Materials 
and Methods section. The murine NIH3T3 nuclei gave a characteristic staining of 
intranuclear bodies (speckles), and the human U2OS nuclei displayed a diffuse 
pattern, indicated by the arrows.  
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Supplementary Figure S3.4 Continued.  
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Supplementary Figure S3.5. U2OS cells express the phosphorylated form of 
Smad2 in the absence of TGF-β1 treatment. 
U2OS cells were starved in serum-free media for 24 h and then were stimulated 
with 2 ng/mL TGF-β1 for 1 h in serum-free condition. Cell lysates were subjected 
to Western blot analysis. Phosphor-Smad2 and total Smad2/3 antibodies were 
used. 
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Supplementary Figure S3.6 NAG-1 attenuates TGF-β signaling without affecting 
Smad2 phosphorylation. 
A, MCF7 cells were transfected with either 3TP or PAI-1 (800 bp promoter) reporter 
constructs with the indicated expression vectors, and luciferase was measured. B, 
MCF-10A cells were transfected with SBE4 reporter with indicated NAG-1 expression 
vectors, followed by luciferase assay. Mean values with SD from three replicates are 
shown. *P < 0.05, ***P < 0.001, compared to TGF-β1-treated empty vector-
transfected cells. C, A549 cells were transfected with control LacZ expression vector 
or pNAG-1-V5/His ΔNES expression vector. After treatment with TGF-β1 (2 ng/mL) 
for 1 h, the media were replaced with fresh media containing 10 μM cycloheximide 
(CHX), and cell lysates were isolated at the indicated time points followed by 
subcellular fractionation. Cytoplasmic and nuclear fractions were subjected to 
Western blot analysis using pSmad2 and Smad2 antibodies. D, DNA pull-down 
followed by Western analysis with anti-Smad2/3 and anti-Smad4 antibodies. Cell 
lysates from either empty vector or wildtype-NAG-1 expression vector were 
transfected into MCF-10A cells incubated with SBE oligos, as described in Materials 
and Methods. SBE-bound Smad proteins were reduced in NAG-1-expressing MCF-
10A cells compared to empty vector-transfected MCF-10A cells.  
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Supplementary Figure S3.6 Continued. 
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Supplementary Figure S3.7 NAG-1 attenuates TGF-β1-induced EMT marker. 
MDA-MB-231cells were transfected with the indicated vectors and then were 
stimulated with TGF-β1 for 48 h. Whole cell lysates (30 μg) were subjected to 
Western blot with anti-Snail, anti-Slug, and anti-V5 antibodies.  
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Supplementary Figure S3.8 NAG-1 does not bind to Smad2/3/4.  
A, HEK293 cells were transfected with pNAG-1/V5/His WT NAG-1 and Flag-
tagged Smad2 expression vector. Cell lysates were subjected to 
immunoprecipitation using 2 μg V5 or normal IgG antibodies, and then subjected 
to Western blot analysis using Flag or V5 antibodies. The whole cell lysate (WCL) 
was loaded with 30 μg. B, HEK293 cells were transfected with pNAG-1/V5/His 
WT NAG-1 expression vector; then the cells were stimulated with 2 ng/ml TGF-β1 
for 3 h. Cell lysates were subjected to immunoprecipitation using 2 μg V5 
antibody followed by Western blot analysis using Smad3 or Smad4 antibodies 
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Supplementary Table S3.1. Primer sequences used to construct plasmids in this 
study. 
 
Construct Direction Sequence (5’-3’) 
NAG-1-GFP-
WT 
Forward GCCATGCCCGGGCAAGAACTC 
Reverse ATATGCAGTGGCAGTCTTTGGC 
NAG-1-GFP-
Δ2-29 
Forward CACAGCCATGCTGTCTCTGGCCGAGGCGAG 
Reverse CCAGAGACAGCATGGCTGTGCAGGTTGCCC 
NAG-1-GFP-
Δ2-13 
Forward CTGCACAGCCATGCTCCTGGTGTTGCTGGT 
Reverse CCAGGAGCATCATGGCTGTGCAGGTTGCCC 
NAG-1-GFP-
N70A 
Forward GCTGCGGGCCGCCCAGAGCTGGGAAGATTCGA 
Reverse TCGAATCTTCCCAGCTCTGGGCGGCCCGCAGC 
NAG-1-V5-
WT 
Forward GACAATGCCCGGGCAAGAACT 
Reverse ATATGCAGTGGCAGTCTTTGGC 
NAG-1-V5-
Δ190-197 
Forward GCAAGCCGCCCGCAACGGGGACCACTGTCC 
Reverse CCCCGTTGCGGGCGGCTTGCGGCCGCAAGT 
NAG-1-V5-
Δ211-218 
Forward CGGGCGTTGCTCGCTGGAAGACCTGGGCTG 
Reverse CTTCCAGCGAGCAACGCCCGGGCCCGAGCG 
NAG-1-V5-
Δ2-29 
Forward TGGGACAATGCTGTCTCTGGCCGAGGCGAG 
Reverse CCAGAGACAGCATTGTCCCAAGCTTAACTA 
NAG-1-V5-
Δ30-57 
Forward TGGGGGCGCCAAACGCTACGAGGACCTGCT 
Reverse CGTAGCGTTTGGCGCCCCCATGCGGCAGCC 
NAG-1-V5-
Δ58-85 
Forward AGAGTTGCGGGTCCGGATACTCACGCCAGA 
Reverse GTATCCGGACCCGCAACTCTCGGAATCTGG 
NAG-1-V5-
Δ86-95 
Forward GGCCCCTGCAGGATCCGGCGGCCACCTGCA 
Reverse CGCCGGATCCTGCAGGGGCCGGGACGAGGT 
NAG-1-V5-
Δ96-105 
Forward AGTGCGGCTGTCTCGGGCCGCCCTTCCCGA 
Reverse CGGCCCGAGACAGCCGCACTTCTGGCGTGA 
NAG-1-V5-
Δ106-113 
Forward CCTGCGTATCCTCCCCGAGGCCTCCCGCCT 
Reverse CCTCGGGGAGGATACGCAGGTGCAGGTGGC 
NAG-1-V5-
Δ114-127 
Forward TCCCGAGGGGTCCCCGACGGCGTCAAGGTC 
Reverse CCGTCGGGGACCCCTCGGGAAGGGCGGCCC 
NAG-1-V5-
Δ128-141 
Forward GTTCCGGCTGCGGCGTCAGCTCAGCCTTGC 
Reverse GCTGACGCCGCAGCCGGAACAGAGCCCGGT 
NAG-1-V5-
Δ142-169 
Forward ACGACCGCTGCTGGCAGAATCTTCGTCCGC 
Reverse ATTCTGCCAGCAGCGGTCGTGTCACGTCCC 
NAG-1-V5-
Δ14-29 
Forward TGGCTCTCAGCTGTCTCTGGCCGAGGCGAG 
Reverse CCAGAGACAGCTGAGAGCCATTCACCGTCC 
NAG-1-V5-
R193A 
Forward CAGGGGGCGCGCCAGAGCGCGTGCGCGCAACG 
Reverse CGTTGCGCGCACGCGCTCTGGCGCGCCCCCTG 
NAG-1-V5-
ΔNES 
Forward TGGCTCTCAGTCGTGGCTGCCGCATGGGGG 
Reverse GCAGCCACGACTGAGAGCCATTCACCGTCC 
NAG-1-V5-
mutNES 
Forward CTCTCAGATGCCCCCGGTGCCGCCCGTGCTCTCGTGGCTG 
Reverse CAGCCACGAGAGCACGGGCGGCACCGGGGGCATCTGAGAG 
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Supplementary Table S3.2 Differentially expressed genes under U2OS and U2OS-
tet condition. 
Gene Locus 
Sample 
1 
Sampl
e 2 
Statu
s 
Value 
1 
Valu
e 
2 
log2 
(fold 
chang
e) 
Test 
stat 
P 
value 
Q 
value 
signific
ant 
RPE65 
chr1:6885
1224-
68915642 
U2OS U2OStet OK 
50.010
3 
59.53
49 
0.2515
08 
-
5.925
84 
3.11E-
09 
2.19E
-06 
yes 
ATP13A2 
chr1:1731
2452-
17338423 
U2OS U2OStet OK 
19.452
3 
15.64
98 
-
0.3137
9 
4.669
55 
3.02E-
06 
0.001
01 
yes 
EBNA1BP
2 
chr1:4362
9844-
43720029 
U2OS U2OStet OK 
133.41
4 
148.1
38 
0.1510
41 
-
3.821
83 
0.00013
2463 
0.022
33 
yes 
NES 
chr1:1566
38555-
15664718
9 
U2OS U2OStet OK 
26.566
5 
23.78
1 
-0.1598 
3.596
39 
0.00032
2663 
0.043
91 
yes 
ANKRD36
BP1 
chr1:1681
95254-
16822234
3 
U2OS U2OStet OK 
3.1588
8 
2.650
61 
-
0.2530
9 
3.976
24 
7.00E-
05 
0.013
47 
yes 
RGS16 
chr1:1825
67757-
18257354
8 
U2OS U2OStet OK 
13.307
8 
10.72
21 
-
0.3116
8 
4.795
32 
1.62E-
06 
0.000
59 
yes 
TNNT2 
chr1:2013
28141-
20134680
5 
U2OS U2OStet OK 
10.258
5 
13.71
61 
0.4190
53 
-
3.831
83 
0.00012
7195 
0.021
63 
yes 
C1orf35 
chr1:2282
88427-
22829102
2 
U2OS U2OStet OK 
8.8674
5 
11.33
99 
0.3548
21 
-
3.867
68 
0.00010
9876 
0.019
2 
yes 
RPS24 
chr10:797
93517-
79816571 
U2OS U2OStet OK 
2414.3
1 
2640.
85 
0.1293
94 
-
3.621
23 
0.00029
3203 
0.041
34 
yes 
NRP1 
chr10:334
66418-
33623920 
U2OS U2OStet OK 
20.205
8 
17.43
08 
-
0.2131
3 
3.711
41 
0.00020
6104 
0.031
29 
yes 
LOXL4 
chr10:100
007372-
10002801
2 
U2OS U2OStet OK 
36.355
8 
32.04
09 
-
0.1822
7 
3.748
78 
0.00017
7696 
0.028
45 
yes 
- 
chr10:332
69656-
33371081 
U2OS U2OStet OK 
5.3051
8 
4.541
18 
-
0.2243
4 
3.986
68 
6.70E-
05 
0.013
15 
yes 
GALNTL4 
chr11:112
92420-
11643596 
U2OS U2OStet OK 4.4756 
2.285
91 
-
0.9693
2 
12.48
81 
0 0 yes 
MIR612 
chr11:652
01219-
65213004 
U2OS U2OStet OK 
0.4482
62 
0.270
93 
-0.7264 
4.722
71 
2.33E-
06 
0.000
81 
yes 
CCDC85B 
chr11:656
57874-
65659106 
U2OS U2OStet OK 
23.404
2 
33.49
95 
0.5173
73 
-
7.600
04 
2.95E-
14 
3.75E
-11 
yes 
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Supplementary Table S3.2 Continued. 
GALNTL4 
chr11:112
92420-
11643596 
U2OS 
U2OSte
t 
OK 
12.626
1 
6.831
09 
-
0.8862
2 
9.907 0 0 Yes 
CCDC34 
chr11:273
51057-
27384795 
U2OS U2OStet OK 
21.528
5 
26.22
57 
0.2847
35 
-
4.133
79 
3.57E-
05 
0.008
5 
yes 
H2AFX 
chr11:118
964584-
11896617
7 
U2OS U2OStet OK 
136.85
9 
160.9
63 
0.2340
35 
-
5.839
48 
5.24E-
09 
3.56E
-06 
yes 
PTMS 
chr12:687
5540-
6880118 
U2OS U2OStet OK 
406.39
3 
457.4 
0.1705
82 
-
4.794
86 
1.63E-
06 
0.000
59 
yes 
GABARAP
L1 
chr12:103
65488-
10375724 
U2OS U2OStet OK 54.675 
47.99
05 
-
0.1881
3 
4.016
02 
5.92E-
05 
0.012
12 
yes 
KLRK1 
chr12:105
15570-
10562745 
U2OS U2OStet OK 
51.889
6 
41.34
05 
-
0.3278
9 
4.006
74 
6.16E-
05 
0.012
48 
yes 
CNTN1 
chr12:410
86243-
41466213 
U2OS U2OStet OK 
8.5481
8 
6.472
64 
-
0.4012
6 
5.519
54 
3.40E-
08 
1.75E
-05 
yes 
PA2G4 
chr12:564
98102-
56507694 
U2OS U2OStet OK 
135.41
4 
149.8
79 
0.1464
21 
-
3.781
67 
0.00015
5781 
0.025
8 
yes 
RPL41 
chr12:565
10373-
56511616 
U2OS U2OStet OK 
3897.4
2 
4354.
86 
0.1601
06 
-
4.575
09 
4.76E-
06 
0.001
44 
yes 
TUBA1A 
chr12:495
78582-
49582861 
U2OS U2OStet OK 
177.57
3 
203.0
35 
0.1933
15 
-
5.194
1 
2.06E-
07 
8.72E
-05 
yes 
LRIG3 
chr12:592
65936-
59314337 
U2OS U2OStet OK 
11.259
1 
8.804
64 
-
0.3547
5 
4.283
07 
1.84E-
05 
0.004
68 
yes 
FLJ44054 
chr13:114
586609-
11462914
2 
U2OS U2OStet OK 
66.794
4 
58.92
36 
-
0.1808
8 
3.984
32 
6.77E-
05 
0.013
15 
yes 
HMGB1 
chr13:310
32878-
31040081 
U2OS U2OStet OK 
378.83
5 
419.7
9 
0.1480
99 
-
4.351
11 
1.35E-
05 
0.003
63 
yes 
SLITRK6 
chr13:863
66921-
86373483 
U2OS U2OStet OK 
0.5343
55 
0.275
87 
-0.9538 
4.003
93 
6.23E-
05 
0.012
49 
yes 
COL4A1 
chr13:110
801309-
11095949
6 
U2OS U2OStet OK 
38.384
1 
33.13
1 
-
0.2123
3 
5.552
66 
2.81E-
08 
1.52E
-05 
yes 
FRMD6 
chr14:519
55854-
52197444 
U2OS U2OStet OK 
40.331
5 
35.64
4 
-
0.1782
5 
3.726
71 
0.00019
3995 
0.030
5 
yes 
SNAPC1 
chr14:622
28931-
62263146 
U2OS U2OStet OK 
131.49
6 
170.3
06 
0.3731
1 
-
8.469
04 
0 0 yes 
SMOC1 
chr14:703
46113-
70499083 
U2OS U2OStet OK 
6.8539
9 
5.417
03 
-
0.3394
4 
3.845
88 
0.00012
012 
0.020
8 
yes 
JDP2 
chr14:758
94508-
75939714 
U2OS U2OStet OK 
7.8183
1 
9.694
54 
0.3103
15 
-
3.777
42 
0.00015
8462 
0.025
8 
yes 
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Supplementary Table S3.2 Continued. 
SLIRP 
chr14:781
74424-
78183941 
U2OS 
U2OSte
t 
OK 323.35 
365.9
62 
0.1786 
-
3.712
64 
0.00020
5105 
0.031
29 
Yes 
CRIP2 
chr14:105
941130-
10594650
0 
U2OS U2OStet OK 
40.343
6 
46.96
48 
0.2192
39 
-
3.807
45 
0.00014
0408 
0.023
46 
yes 
- 
chr14:503
26419-
50329569 
U2OS U2OStet OK 
88.353
8 
60.88
24 
-
0.5372
7 
11.40
39 
0 0 yes 
BMP4 
chr14:544
16454-
54423554 
U2OS U2OStet OK 
13.887
7 
18.58
03 
0.4199
68 
-
4.707
83 
2.50E-
06 
0.000
85 
yes 
LTBP2 
chr14:749
64885-
75079337 
U2OS U2OStet OK 
14.383
3 
12.25
76 
-
0.2307
3 
4.039
41 
5.36E-
05 
0.011
22 
yes 
AHNAK2 
chr14:105
403441-
10544469
4 
U2OS U2OStet OK 
12.804
1 
11.52
34 
-
0.1520
4 
3.579
85 
0.00034
3797 
0.046
45 
yes 
THBS1 
chr15:398
73279-
39889668 
U2OS U2OStet OK 
32.504
6 
28.45
36 
-
0.1920
4 
4.783
33 
1.72E-
06 
0.000
61 
yes 
CHAC1 
chr15:412
45635-
41248717 
U2OS U2OStet OK 
7.4383
7 
10.10
87 
0.4425
44 
-
4.651
31 
3.30E-
06 
0.001
08 
yes 
DUT 
chr15:486
23620-
48635570 
U2OS U2OStet OK 
75.449
6 
86.89
43 
0.2037
49 
-
4.174
39 
2.99E-
05 
0.007
2 
yes 
FURIN 
chr15:914
11884-
91426687 
U2OS U2OStet OK 
50.943
6 
44.14
6 
-
0.2066
2 
5.193
81 
2.06E-
07 
8.72E
-05 
yes 
BMF 
chr15:403
80056-
40401221 
U2OS U2OStet OK 
7.2859
7 
5.347
53 
-
0.4462
5 
4.839
32 
1.30E-
06 
0.000
49 
yes 
COX5A 
chr15:752
12616-
75230495 
U2OS U2OStet OK 
157.58
6 
177.2
6 
0.1697
29 
-
3.710
37 
0.00020
6954 
0.031
29 
yes 
RPS17 
chr15:828
21160-
82824865 
U2OS U2OStet OK 1163.2 
1379.
55 
0.2461
05 
-
6.903
51 
5.07E-
12 
5.09E
-09 
yes 
ATP6V0C 
chr16:256
3726-
2570224 
U2OS U2OStet OK 
83.715
5 
98.63
28 
0.2365
73 
-
3.985
6 
6.73E-
05 
0.013
15 
yes 
MT2A 
chr16:566
42477-
56643409 
U2OS U2OStet OK 
1164.6
8 
1320.
76 
0.1814
33 
-
4.893
6 
9.90E-
07 
0.000
38 
yes 
MT1E 
chr16:566
59584-
56661024 
U2OS U2OStet OK 
355.52
4 
400.2
67 
0.1710
14 
-
3.950
35 
7.80E-
05 
0.014
72 
yes 
RPL13 
chr16:896
26746-
89634370 
U2OS U2OStet OK 
144.89
3 
163.6
45 
0.1755
82 
-
3.664 
0.00024
831 
0.036
39 
yes 
RPS2 
chr16:201
2061-
2014827 
U2OS U2OStet OK 
2576.6
3 
2832.
3 
0.1364
86 
-
3.946
56 
7.93E-
05 
0.014
81 
yes 
PFN1 
chr17:484
8946-
4851825 
U2OS U2OStet OK 
905.56
1 
1007.
07 
0.1532
73 
-
4.412
85 
1.02E-
05 
0.002
86 
yes 
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KRT17 
chr17:397
75691-
39781043 
U2OS 
U2OSte
t 
OK 
92.137
5 
82.69
33 
-
0.1560
2 
3.677
53 
0.00023
5503 
0.035
33 
Yes 
C1QL1 
chr17:430
37060-
43045644 
U2OS U2OStet OK 
72.076
3 
91.63
76 
0.3464
14 
-
4.853
75 
1.21E-
06 
0.000
46 
yes 
COL1A1 
chr17:482
61456-
48279000 
U2OS U2OStet OK 
112.42
8 
97.70
37 
-
0.2025
1 
5.822
27 
5.81E-
09 
3.81E
-06 
yes 
- 
chr18:765
66211-
76580175 
U2OS U2OStet OK 13.156 
15.58
36 
0.2443
06 
-
5.803
45 
6.50E-
09 
4.13E
-06 
yes 
RPS15 
chr19:143
8362-
1440492 
U2OS U2OStet OK 
637.67
7 
733.5
75 
0.2021
17 
-
5.318
5 
1.05E-
07 
4.86E
-05 
yes 
OAZ1 
chr19:226
9519-
2273487 
U2OS U2OStet OK 
459.21
6 
507.0
73 
0.1430
2 
-
4.032
38 
5.52E-
05 
0.011
43 
yes 
TRAPPC5 
chr19:774
5706-
7747748 
U2OS U2OStet OK 
34.671
1 
44.87 
0.3720
17 
-
4.051
95 
5.08E-
05 
0.010
91 
yes 
RPL18A 
chr19:179
70730-
17974124 
U2OS U2OStet OK 
832.07
5 
911.6
43 
0.1317
55 
-
3.656
7 
0.00025
548 
0.037
15 
yes 
GDF15 
chr19:184
96967-
18499986 
U2OS U2OStet OK 
49.273
6 
1925.
45 
5.2882
4 
-
114.2
52 
0 0 yes 
UBA52 
chr19:186
82371-
18688270 
U2OS U2OStet OK 
146.05
2 
161.3
8 
0.1439
81 
-
3.597
24 
0.00032
1608 
0.043
91 
yes 
- 
chr19:300
74963-
30083332 
U2OS U2OStet OK 
0.6366
52 
0.365
87 
-
0.7991
7 
4.055
69 
5.00E-
05 
0.010
91 
yes 
FTL 
chr19:494
68565-
49470136 
U2OS U2OStet OK 
785.47
2 
857.6
97 
0.1269
09 
-
3.649
11 
0.00026
3149 
0.037
98 
yes 
FAM108A
1 
chr19:187
6974-
1885518 
U2OS U2OStet OK 
26.954
1 
32.17
32 
0.2553
57 
-
3.573
52 
0.00035
2219 
0.047
25 
yes 
CTXN1 
chr19:798
9380-
7991051 
U2OS U2OStet OK 
24.474
3 
30.47
56 
0.3163
87 
-
4.562
93 
5.04E-
06 
0.001
5 
yes 
C19orf43 
chr19:128
41453-
12845529 
U2OS U2OStet OK 
85.251
4 
102.2
43 
0.2622
06 
-
5.304
11 
1.13E-
07 
5.14E
-05 
yes 
GADD45G
IP1 
chr19:130
64971-
13068050 
U2OS U2OStet OK 
55.032
9 
65.66
81 
0.2548
99 
-
4.206
04 
2.60E-
05 
0.006
35 
yes 
JUND 
chr19:183
90562-
18392432 
U2OS U2OStet OK 
51.779
5 
62.53
69 
0.2723
26 
-
5.731
97 
9.93E-
09 
5.91E
-06 
yes 
LRFN1 
chr19:397
97456-
39811499 
U2OS U2OStet OK 
13.631
1 
15.96
6 
0.2280
99 
-
3.769
6 
0.00016
3513 
0.026
4 
yes 
SLC1A5 
chr19:472
78136-
47291842 
U2OS U2OStet OK 
55.671
3 
64.88 
0.2208
39 
-
4.288
12 
1.80E-
05 
0.004
64 
yes 
LBH 
chr2:3045
4396-
30482899 
U2OS U2OStet OK 
38.784
2 
33.78
61 
-
0.1990
4 
4.369
21 
1.25E-
05 
0.003
39 
yes 
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Supplementary Table S3.2 Continued. 
LTBP1 
chr2:3317
1602-
33624575 
U2OS 
U2OSte
t 
OK 
16.338
9 
13.69
16 
-
0.2550
3 
3.964
19 
7.36E-
05 
0.014
03 
Yes 
MTHFD2 
chr2:7442
5689-
74442424 
U2OS U2OStet OK 
109.63
5 
124.7
29 
0.1860
92 
-
4.212
67 
2.52E-
05 
0.006
24 
yes 
TMSB10 
chr2:8513
2762-
85133799 
U2OS U2OStet OK 
1996.8
1 
2201 
0.1404
64 
-
4.098
13 
4.17E-
05 
0.009
68 
yes 
LOC44090
5 
chr2:1307
83571-
13082478
4 
U2OS U2OStet OK 
2.1061
5 
1.683
28 
-
0.3233
4 
4.624
89 
3.75E-
06 
0.001
17 
yes 
TNFAIP6 
chr2:1522
14105-
15223656
2 
U2OS U2OStet OK 
5.8843
2 
4.069
31 
-
0.5320
9 
4.328
08 
1.50E-
05 
0.003
93 
yes 
NOP58 
chr2:2031
30514-
20316838
4 
U2OS U2OStet OK 
75.611
7 
83.88
47 
0.1497
97 
-
3.673
86 
0.00023
8912 
0.035
48 
yes 
PTMA 
chr2:2325
73234-
23257825
0 
U2OS U2OStet OK 824.17 
905.7
95 
0.1362
44 
-
3.878
56 
0.00010
5076 
0.018
53 
yes 
SNRPG 
chr2:7050
8505-
70520869 
U2OS U2OStet OK 
356.55
5 
413.4
76 
0.2136
77 
-
5.162
07 
2.44E-
07 
0.000
1 
yes 
LINC0011
6 
chr2:1109
69105-
11098051
7 
U2OS U2OStet OK 
7.0947
4 
8.990
87 
0.3417
1 
-
3.778
16 
0.00015
7994 
0.025
8 
yes 
LIMS3 
chr2:1111
60495-
11123065
2 
U2OS U2OStet OK 
1.9338
5 
0.082
35 
-
4.5535
2 
7.957
11 
1.78E-
15 
2.82E
-12 
yes 
IGFBP5 
chr2:2175
36827-
21756027
2 
U2OS U2OStet OK 
29.852
3 
21.99
58 
-
0.4406
2 
10.67
94 
0 0 yes 
EPHA4 
chr2:2222
82746-
22243977
4 
U2OS U2OStet OK 
1.9933
3 
1.437
41 
-
0.4717
1 
4.418
36 
9.95E-
06 
0.002
83 
yes 
ID1 
chr20:301
93085-
30194317 
U2OS U2OStet OK 107.23 
145.3
31 
0.4386
32 
-
8.915
74 
0 0 yes 
CEBPB 
chr20:488
07119-
48809227 
U2OS U2OStet OK 
15.109
9 
17.87
89 
0.2427
71 
-
3.619
54 
0.00029
5131 
0.041
34 
yes 
- 
chr20:571
97836-
57210985 
U2OS U2OStet OK 
5.6984
4 
4.269
81 
-0.4164 
6.311
94 
2.76E-
10 
2.19E
-07 
yes 
RPS21 
chr20:609
62120-
60963576 
U2OS U2OStet OK 
1541.6
6 
1715 
0.1537
24 
-
4.224
21 
2.40E-
05 
0.006
01 
yes 
CST3 
chr20:236
14293-
23618574 
U2OS U2OStet OK 78.154 
89.74
03 
0.1994
38 
-
3.631
15 
0.00028
2162 
0.040
11 
yes 
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Supplementary Table S3.2 Continued. 
TGM2 
chr20:367
56863-
36793700 
U2OS 
U2OSte
t 
OK 
19.049
3 
15.97
69 
-
0.2537
5 
4.461
47 
8.14E-
06 
0.002
39 
Yes 
PMEPA1 
chr20:562
23447-
56286592 
U2OS U2OStet OK 
25.060
7 
19.34
73 
-0.3733 
6.730
62 
1.69E-
11 
1.61E
-08 
yes 
PSMA7 
chr20:607
11790-
60718474 
U2OS U2OStet OK 464.14 
508.5
18 
0.1317
39 
-
3.672
4 
0.00024
028 
0.035
48 
yes 
- 
chr20:572
11326-
57218179 
U2OS U2OStet OK 
1.0768
3 
0.773
55 
-
0.4772
3 
3.908
03 
9.31E-
05 
0.016
61 
yes 
- 
chr21:982
5436-
9826332 
U2OS U2OStet OK 
52.606
8 
77.67
33 
0.5621
69 
-
3.938
63 
8.19E-
05 
0.015
16 
yes 
MIF 
chr22:242
35896-
24241117 
U2OS U2OStet OK 
1143.5
3 
1385.
34 
0.2767
48 
-
7.729
16 
1.09E-
14 
1.48E
-11 
yes 
TIMP3 
chr22:329
08539-
33454377 
U2OS U2OStet OK 
19.807
4 
15.74
29 
-
0.3313
4 
7.159
85 
8.08E-
13 
9.05E
-10 
yes 
ATF4 
chr22:399
16568-
39918691 
U2OS U2OStet OK 
330.38
1 
370.3
46 
0.1647
46 
-
4.630
89 
3.64E-
06 
0.001
16 
yes 
MN1 
chr22:281
32565-
28198388 
U2OS U2OStet OK 
30.117
5 
25.38
92 
-
0.2463
9 
4.058
82 
4.93E-
05 
0.010
91 
yes 
BHLHE40 
chr3:5021
096-
5026865 
U2OS U2OStet OK 
17.030
3 
14.56
97 
-
0.2251
4 
4.040
45 
5.33E-
05 
0.011
22 
yes 
LMCD1 
chr3:8543
484-
8609806 
U2OS U2OStet OK 
11.936
4 
9.505
59 
-
0.3285
2 
3.908
86 
9.27E-
05 
0.016
61 
yes 
CCDC72 
chr3:4848
1685-
48485537 
U2OS U2OStet OK 
462.87
9 
535.1
71 
0.2093
63 
-
5.104
24 
3.32E-
07 
0.000
13 
yes 
- 
chr3:1106
05903-
11069024
3 
U2OS U2OStet OK 
20.335
8 
18.21
78 
-
0.1586
8 
3.607
85 
0.00030
8741 
0.042
93 
yes 
H1FX 
chr3:1290
33613-
12904341
2 
U2OS U2OStet OK 
129.89
8 
151.3
75 
0.2207
45 
-
5.369
82 
7.88E-
08 
3.85E
-05 
yes 
SERP1 
chr3:1502
59779-
15030380
3 
U2OS U2OStet OK 
31.255
1 
36.08
92 
0.2074
74 
-
3.636
17 
0.00027
6722 
0.039
64 
yes 
HMGB2 
chr4:1742
52526-
17425559
5 
U2OS U2OStet OK 
104.46
3 
123.4
37 
0.2407
82 
-
5.362
72 
8.20E-
08 
3.90E
-05 
yes 
RHOBTB3 
chr5:9506
3687-
95132071 
U2OS U2OStet OK 
48.489
2 
54.31
96 
0.1638
09 
-
3.725
02 
0.00019
53 
0.030
5 
yes 
TGFBI 
chr5:1353
64583-
13539950
7 
U2OS U2OStet OK 
31.222
3 
23.10
96 
-
0.4340
9 
8.098
72 
6.66E-
16 
1.15E
-12 
yes 
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Supplementary Table S3.2 Continued. 
SLC12A7 
chr5:1050
488-
1112392 
U2OS 
U2OSte
t 
OK 
33.504
8 
27.64
13 
-
0.2775
5 
5.622
38 
1.88E-
08 
1.09E
-05 
Yes 
PLK2 
chr5:5774
9809-
57755966 
U2OS U2OStet OK 
43.177
3 
50.88
41 
0.2369
43 
-
5.549
21 
2.87E-
08 
1.52E
-05 
yes 
TBCA 
chr5:7698
6994-
77072185 
U2OS U2OStet OK 
85.115
4 
97.83
17 
0.2008
82 
-
3.727
26 
0.00019
3574 
0.030
5 
yes 
HMGA1 
chr6:3420
4576-
34214010 
U2OS U2OStet OK 266.58 
301.2
12 
0.1762
11 
-
4.108
74 
3.98E-
05 
0.009
36 
yes 
IER3 
chr6:3071
0975-
30712327 
U2OS U2OStet OK 
58.576
4 
48.31
21 
-
0.2779
4 
5.251
17 
1.51E-
07 
6.70E
-05 
yes 
- 
chr6:4460
8572-
44621571 
U2OS U2OStet OK 
16.531
5 
11.77
53 
-
0.4894
6 
5.452
11 
4.98E-
08 
2.50E
-05 
yes 
CTGF 
chr6:1322
69316-
13227251
8 
U2OS U2OStet OK 
77.661
3 
69.81
94 
-
0.1535
7 
3.722
1 
0.00019
7574 
0.030
6 
yes 
SLC2A12 
chr6:1343
08718-
13437378
9 
U2OS U2OStet OK 
7.5079
7 
5.637
96 
-
0.4132
5 
6.097
59 
1.08E-
09 
7.89E
-07 
yes 
CITED2 
chr6:1396
93396-
13969578
5 
U2OS U2OStet OK 
55.988
6 
69.84
78 
0.3190
81 
-
7.091
93 
1.32E-
12 
1.40E
-09 
yes 
EZR 
chr6:1591
86772-
15924045
6 
U2OS U2OStet OK 
49.106
5 
54.69
56 
0.1555
11 
-
3.602
15 
0.00031
5591 
0.043
57 
yes 
FSCN1 
chr7:5632
435-
5646287 
U2OS U2OStet OK 
118.60
6 
131.6
92 
0.1509
86 
-
4.066
7 
4.77E-
05 
0.010
69 
yes 
CLDN4 
chr7:7324
5192-
73247015 
U2OS U2OStet OK 
30.985
4 
24.08
84 
-
0.3632
5 
6.366
13 
1.94E-
10 
1.61E
-07 
yes 
SERPINE1 
chr7:1007
69956-
10078254
7 
U2OS U2OStet OK 
22.448
5 
18.92
29 
-
0.2464
8 
4.612
96 
3.97E-
06 
0.001
22 
yes 
CAV1 
chr7:1161
64838-
11620123
9 
U2OS U2OStet OK 
121.75
4 
153.6
46 
0.3356
5 
-
7.774
71 
7.55E-
15 
1.11E
-11 
yes 
- 
chr7:5792
0454-
57929601 
U2OS U2OStet OK 
7.1358
8 
9.962
56 
0.4814
24 
-
6.567
2 
5.13E-
11 
4.65E
-08 
yes 
SPDYE7P 
chr7:7233
3317-
72339655 
U2OS U2OStet OK 
3.9685
2 
2.860
21 
-
0.4724
8 
6.394
77 
1.61E-
10 
1.39E
-07 
yes 
ASNS 
chr7:9748
1428-
97501854 
U2OS U2OStet OK 
40.904
3 
47.63
67 
0.2198
22 
-
4.051
06 
5.10E-
05 
0.010
91 
yes 
EIF4EBP1 
chr8:3788
8019-
37917883 
U2OS U2OStet OK 
74.373
4 
89.18
71 
0.2620
48 
-
5.029
97 
4.91E-
07 
0.000
19 
yes 
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Supplementary Table S3.2 Continued. 
ZMAT4 
chr8:4038
8110-
40755343 
U2OS 
U2OSte
t 
OK 
0.4699
7 
1.748
57 
1.8955
4 
-
4.094
83 
4.22E-
05 
0.009
7 
Yes 
PABPC1 
chr8:1017
15143-
10173431
5 
U2OS U2OStet OK 
610.24
5 
668.3
41 
0.1311
97 
-
3.837
3 
0.00012
4394 
0.021
35 
yes 
ANXA1 
chr9:7576
6780-
75785307 
U2OS U2OStet OK 
327.94
4 
360.8
29 
0.1378
64 
-
3.907
33 
9.33E-
05 
0.016
61 
yes 
PSAT1 
chr9:8091
2058-
80945009 
U2OS U2OStet OK 
27.088
9 
33.29
47 
0.2975
88 
-
5.571
33 
2.53E-
08 
1.42E
-05 
yes 
MRPL41 
chr9:1404
46308-
14044700
7 
U2OS U2OStet OK 
88.646
4 
111.9
16 
0.3362
81 
-
5.775
16 
7.69E-
09 
4.72E
-06 
yes 
TMEM2 
chr9:7429
8281-
74383822 
U2OS U2OStet OK 
18.844
4 
16.44
45 
-
0.1965
3 
4.381
01 
1.18E-
05 
0.003
26 
yes 
ABCA1 
chr9:1075
43056-
10769476
2 
U2OS U2OStet OK 1.9841 
1.529
11 
-
0.3757
9 
4.346
43 
1.38E-
05 
0.003
66 
yes 
TNC 
chr9:1177
81853-
11788133
0 
U2OS U2OStet OK 
32.458
9 
28.65
07 
-
0.1800
5 
4.077
84 
4.55E-
05 
0.010
31 
yes 
RPL35 
chr9:1276
15754-
12762424
0 
U2OS U2OStet OK 
858.71
3 
951.2
44 
0.1476
39 
-
3.917
93 
8.93E-
05 
0.016
36 
yes 
XAGE1A,X
AGE1E 
chrX:5223
8809-
52243953 
U2OS U2OStet OK 
120.24
4 
76.78
33 
-0.6471 
8.804
37 
0 0 yes 
XAGE1C,X
AGE1D 
chrX:5251
1760-
52516904 
U2OS U2OStet OK 
122.22
7 
86.12
6 
-
0.5050
4 
7.183
72 
6.78E-
13 
8.08E
-10 
yes 
PCSK1N 
chrX:4868
9505-
48693960 
U2OS U2OStet OK 
14.146
3 
21.17
19 
0.5817
33 
-
6.252
84 
4.03E-
10 
3.07E
-07 
yes 
XAGE1C 
chrX:5225
5219-
52260363 
U2OS U2OStet OK 
210.47
1 
308.6
48 
0.5523
39 
-
10.94
5 
0 0 yes 
XAGE1A,X
AGE1D 
chrX:5252
8159-
52533303 
U2OS U2OStet OK 
103.76
5 
175.5
15 
0.7582
77 
-
12.52
88 
0 0 yes 
XAGE1C 
chrX:5254
1053-
52546197 
U2OS U2OStet OK 73.705 
56.87
92 
-
0.3738
6 
4.646
91 
3.37E-
06 
0.001
09 
yes 
BCYRN1 
chrX:7043
0034-
70948962 
U2OS U2OStet OK 
225.26
4 
645.5
3 
1.5188
6 
-
4.440
83 
8.96E-
06 
0.002
59 
yes 
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Supplementary Table S3.3. Primer sets for real-time RT-PCR in this study. 
Gene Direction Sequence (5’-3’) 
COL1A1 Forward GTCCTGTCGGCCCTGTTG 
Reverse CTTCTCTTGAGGTGGCTGGG 
TIMP3 Forward ATGGCAAGATGTACACGGGG 
Reverse GGGGTCTGTGGCATTGATGA 
TGM2 Forward TACGATGCGCCCTTTGTCTT 
Reverse GTGTTGTTGGTGATGTGGGC 
TGFBI Forward TAACGGCCAGTACACGCTTT 
Reverse TGGCTGTGGACACATCAGAC 
LTBP1 Forward GGGATGGGGAGATAACTGCG 
Reverse TTTCTGACGCATCCAGGACC 
LTBP2 Forward AAGTGACCCCCTCCACTGAT 
Reverse ATCACACTCGCAGTGGTACG 
SERPINE1 Forward GCCAGTGGAAGACTCCCTTC 
Reverse CTCTAGGGGCTTCCTGAGGT 
PMEPA1 Forward CCTCAGAAGGATGCCTGTGG 
Reverse CCAGCCTGGCACTATCCATC 
HMGA1 Forward GGAAAAGGACGGCACTGAGA 
Reverse GAGGACTCCTGCGAGATGC 
IGFBP5 Forward AACGAAAAGAGCTACCGCGA 
Reverse GGGAAGGTTTGCACTGCTTT 
RPLP0 Forward AATCTCCAGGGGCACCATTG 
Reverse ATCTGCAGACAGACACTGGC 
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